Romidepsin (FK228, Depsipeptide)

Name: Romidepsin (FK228, Depsipeptide)
Brand: Selleck Chemicals
SKU: S3020
Rating: 5 (150 reviews)

For research use only.

Catalog No.S3020 Synonyms: FR 901228, NSC 630176

150 publications

Romidepsin (FK228, Depsipeptide) Chemical Structure

CAS No. 128517-07-7

Romidepsin (FK228, Depsipeptide, FR 901228, NSC 630176) is a potent HDAC1 and HDAC2 inhibitor with IC50 of 36 nM and 47 nM in cell-free assays, respectively. Romidepsin (FK228/depsipeptide) controls growth and induces apoptosis in neuroblastoma tumor cells.

Selleck's Romidepsin (FK228, Depsipeptide) has been cited by 150 publications

Cell, 2020, 182(3):685-712.e19

PubMed: 32645325 ( click the link to review the publication )

Nat Biotechnol, 2020, 10.1038/s41587-019-0388-4

PubMed: 31959954 ( click the link to review the publication )

Nature, 2017, 551(7679):247-250

PubMed: 29088702 ( click the link to review the publication )

Cancer Discov, 2017, 7(12):1450-1463

PubMed: 28963352 ( click the link to review the publication )

Nucleic Acids Res, 2021, 49(4):2390-2399

PubMed: 33544854 ( click the link to review the publication )

Neuro Oncol, 2021, 23(3):376-386

PubMed: 33130903 ( click the link to review the publication )

Cancers (Basel), 2021, 13(6)1376

PubMed: 33803654 ( click the link to review the publication )

Cancers (Basel), 2021, 13(2)E259

PubMed: 33445642 ( click the link to review the publication )

Genes (Basel), 2021, 12(2)260

PubMed: 33670166 ( click the link to review the publication )

Dev Dyn, 2021, 10.1002/dvdy.294

PubMed: 33410213 ( click the link to review the publication )

SLAS Discov, 2021, 2472555220983810

PubMed: 33427012 ( click the link to review the publication )

Transl Psychiatry, 2021, 11(1):99

PubMed: 33542189 ( click the link to review the publication )

EBioMedicine, 2021, 65:103241

PubMed: 33647768 ( click the link to review the publication )

Eur J Immunol, 2021, 10.1002/eji.202048892

PubMed: 33555624 ( click the link to review the publication )

Clin Epigenetics, 2021, 13(1):41

PubMed: 33632300 ( click the link to review the publication )

J Dermatol Sci, 2021, S0923-1811(21)00005-0

PubMed: 33531202 ( click the link to review the publication )

Life Sci, 2021, 271:119127

PubMed: 33515561 ( click the link to review the publication )

Nat Commun, 2020, 11(1):5775

PubMed: 33188175 ( click the link to review the publication )

EMBO Rep, 2020, 21:e50162

PubMed: 32314873 ( click the link to review the publication )

Int J Cancer, 2020, 10.1002/ijc.33046

PubMed: 32599665 ( click the link to review the publication )

PLoS Pathog, 2020, 16(2):e1008151

PubMed: 32109259 ( click the link to review the publication )

Cells, 2020, 10;9(6):E1447

PubMed: 32532133 ( click the link to review the publication )

J Immunol, 2020, 204(5):1242-1254

PubMed: 31988180 ( click the link to review the publication )

J Virol, 2020, 16;94(9) pii: e01845-19

PubMed: 32051267 ( click the link to review the publication )
Cancer Cell Int, 2020, 19;20:58

PubMed: 32099531 ( click the link to review the publication )

HIV Med, 2020, 21(11):747-757

PubMed: 33369029 ( click the link to review the publication )

Am J Transl Res, 2020, 12(10):6187-6203

PubMed: 33194023 ( click the link to review the publication )

Biochem Biophys Res Commun, 2020, 4;526(3):612-617

PubMed: 32247610 ( click the link to review the publication )

Hum Cell, 2020, 10.1007/s13577-020-00420-z

PubMed: 32870449 ( click the link to review the publication )

Hum Cell, 2020, 10.1007/s13577-020-00425-8

PubMed: 32886306 ( click the link to review the publication )

Blood Adv, 2020, 4(5):819-829

PubMed: 32126142 ( click the link to review the publication )

Sci Rep, 2020, 10(1):12864

PubMed: 32733053 ( click the link to review the publication )

Cancer Immunol Immunother, 2020, 10.1007/s00262-020-02653-1

PubMed: 32632663 ( click the link to review the publication )

Oncotarget, 2020, 11(37):3432-3442

PubMed: 32973968 ( click the link to review the publication )

Cancers (Basel), 2020, 12(12)E3589

PubMed: 33266275 ( click the link to review the publication )

Genes Chromosomes Cancer, 2020, 10.1002/gcc.22884

PubMed: 32614991 ( click the link to review the publication )

Front Immunol, 2020, 11:1746

PubMed: 33013828 ( click the link to review the publication )

Med Sci Monit, 2020, 26:e918528

PubMed: 31954012 ( click the link to review the publication )

PeerJ, 2020, 8:e10321

PubMed: 33282555 ( click the link to review the publication )

Epigenetics, 2020, 15(4):369-385

PubMed: 31533525 ( click the link to review the publication )

J Clin Invest, 2020, 135711

PubMed: 33270606 ( click the link to review the publication )

Nat Commun, 2019, 10(1):2189

PubMed: 31097698 ( click the link to review the publication )

J Thorac Oncol, 2019, 14(3):513-526

PubMed: 30521971 ( click the link to review the publication )

Clin Cancer Res, 2019, 10.1158/1078-0432

PubMed: 30979734 ( click the link to review the publication )

Haematologica, 2019, 10.3324/haematol.2018.211110

PubMed: 30846494 ( click the link to review the publication )

Clin Infect Dis, 2019, 10.1093/cid/ciz108

PubMed: 30753360 ( click the link to review the publication )

Clin Cancer Res, 2019, 10.1158/1078-0432.CCR-19-2152

PubMed: 31772119 ( click the link to review the publication )

Cell Rep, 2019, 29(9):2783-2795

PubMed: 31775045 ( click the link to review the publication )
Elife, 2019, 10.7554/eLife.44306

PubMed: 31050342 ( click the link to review the publication )

J Hematol Oncol, 2019, 12(1):30

PubMed: 30885250 ( click the link to review the publication )

Mol Ther, 2019, 27(5):1039-1050

PubMed: 30852137 ( click the link to review the publication )

Cancers (Basel), 2019, 11(5)E645

PubMed: 31083396 ( click the link to review the publication )

Cancers (Basel), 2019, 11(12)E1871

PubMed: 31769432 ( click the link to review the publication )

PLoS Pathog, 2019, 15(8):e1007991

PubMed: 31425551 ( click the link to review the publication )

Acta Pharm Sin B, 2019, 9(5):937-951

PubMed: 31649844 ( click the link to review the publication )

Front Immunol, 2019, 9:3162

PubMed: 30723480 ( click the link to review the publication )

Mol Cancer Ther, 2019, 18(5):900-908

PubMed: 30824609 ( click the link to review the publication )

Oncologist, 2019, 24(8):e740-e748

PubMed: 30696721 ( click the link to review the publication )

Mol Neurobiol, 2019, 10.1007/s12035-019-1565-7

PubMed: 30963442 ( click the link to review the publication )

AIDS, 2019, 33(2):199-209

PubMed: 30562171 ( click the link to review the publication )

Pharmacol Res, 2019, 142:192-204

PubMed: 30807866 ( click the link to review the publication )

Arthritis Res Ther, 2019, 21(1):50

PubMed: 30728075 ( click the link to review the publication )

Apoptosis, 2019, 24(5-6):404-413

PubMed: 30997620 ( click the link to review the publication )

J Biol Chem, 2019, 294(14):5576-5589

PubMed: 30745362 ( click the link to review the publication )

Exp Cell Res, 2019, 375(2):106-112

PubMed: 30579954 ( click the link to review the publication )

BMC Cancer, 2019, 19(1):79

PubMed: 30651077 ( click the link to review the publication )

Biochem Biophys Res Commun, 2019, 510(2):278-283

PubMed: 30686534 ( click the link to review the publication )

ACS Omega, 2019, 4(22):19895-19904

PubMed: 31788622 ( click the link to review the publication )

Virus Res, 2019, 269:197631

PubMed: 31136823 ( click the link to review the publication )

Oncotarget, 2019, 10(55):5671-5679

PubMed: 31620242 ( click the link to review the publication )

J Nanobiotechnology, 2019, 17(1):69

PubMed: 31113488 ( click the link to review the publication )

J Virus Erad, 2019, 5(3):133-137

PubMed: 31700655 ( click the link to review the publication )
Blood, 2018, 131(4):397-407

PubMed: 29141948 ( click the link to review the publication )

J Clin Invest, 2018, 128(10):4413-4428

PubMed: 30148456 ( click the link to review the publication )

Nat Commun, 2018, 9(1):2024

PubMed: 29789628 ( click the link to review the publication )

Haematologica, 2018, 103(4):679-687

PubMed: 29305415 ( click the link to review the publication )

Int J Cancer, 2018, 143(6):1388-1401

PubMed: 29633255 ( click the link to review the publication )

MBio, 2018, 9(6)

PubMed: 30425153 ( click the link to review the publication )

Clin Epigenetics, 2018, 10:01

PubMed: 29312470 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(12):2767-2779

PubMed: 30232145 ( click the link to review the publication )

Cell Prolif, 2018, 51(3):e12447

PubMed: 29484736 ( click the link to review the publication )

J Virol, 2018, 92(13)

PubMed: 29643247 ( click the link to review the publication )

J Virol, 2018, 92(6)

PubMed: 29298886 ( click the link to review the publication )

Sci Rep, 2018, 8(1):1400

PubMed: 29362442 ( click the link to review the publication )

Stem Cells Int, 2018, 2018:2379546

PubMed: 29731773 ( click the link to review the publication )

Stem Cells Dev, 2018, 27(17):1215-1225

PubMed: 30032710 ( click the link to review the publication )

Cancers (Basel), 2018, 10(12)E505

PubMed: 30544928 ( click the link to review the publication )

Curr Protoc Pharmacol, 2018, 81(1):e41

PubMed: 29927058 ( click the link to review the publication )

Genome Res, 2018, 10.1101/gr.227272.117

PubMed: 29429976 ( click the link to review the publication )

Nat Neurosci, 2018, 21(4):564-575

PubMed: 29531362 ( click the link to review the publication )

JCI Insight, 2018, 3(22)125568

PubMed: 30429379 ( click the link to review the publication )

Nat Commun, 2017, 8(1):403

PubMed: 28864822 ( click the link to review the publication )

Nat Commun, 2017, 8(1):939

PubMed: 29038521 ( click the link to review the publication )

Genes Dev, 2017, 31(17):1770-1783

PubMed: 28982760 ( click the link to review the publication )

Cancer Immunol Res, 2017, 5(7):604-616

PubMed: 28615266 ( click the link to review the publication )

Clin Cancer Res, 2017, 23(12):3084-3096

PubMed: 27993968 ( click the link to review the publication )
Arch Toxicol, 2017, 91(5):2191-2208

PubMed: 27807597 ( click the link to review the publication )

Cancer Discov, 2017, 7(12):1450-1463

PubMed: 28963352 ( click the link to review the publication )

FEBS J, 2017, 284(23):4035-4050

PubMed: 28985013 ( click the link to review the publication )

Biochem Pharmacol, 2017, 127:90-100

PubMed: 28012958 ( click the link to review the publication )

Int J Mol Sci, 2017, 18(5)

PubMed: 28481295 ( click the link to review the publication )

J Pharmacol Exp Ther, 2017, 363(2):211-220

PubMed: 28860353 ( click the link to review the publication )

Acta Pharmacol Sin, 2017, 38(4):551-560

PubMed: 28112184 ( click the link to review the publication )

Int J Parasitol Drugs Drug Resist, 2017, 7(1):42-50

PubMed: 28107750 ( click the link to review the publication )

JCI Insight, 2017, 2(1):e85811

PubMed: 28097226 ( click the link to review the publication )

Oncotarget, 2017, 8(4):6319-6329

PubMed: 28030834 ( click the link to review the publication )

JCI Insight, 2017, 2(6):e90196

PubMed: 28352655 ( click the link to review the publication )

Oncotarget, 2017, 9(3):3908-3921

PubMed: 29423093 ( click the link to review the publication )

Oncotarget, 2017, 8(30-:48737-48754

PubMed: 28467787 ( click the link to review the publication )

Ann Oncol, 2016, 27(3):508-13

PubMed: 26658891 ( click the link to review the publication )

EMBO Mol Med, 2016, 8(2):117-38

PubMed: 26681773 ( click the link to review the publication )

Clin Cancer Res, 2016, 22(16):4119-32

PubMed: 26964571 ( click the link to review the publication )

Kidney Int, 2016, 89(2):317-26

PubMed: 26509586 ( click the link to review the publication )

EBioMedicine, 2016, 8:217-229

PubMed: 27428432 ( click the link to review the publication )

PLoS Pathog, 2016, 12(4):e1005545

PubMed: 27082643 ( click the link to review the publication )

J Virol, 2016, 90(20):9018-28

PubMed: 27466424 ( click the link to review the publication )

Sci Rep, 2016, 6:30749

PubMed: 27480951 ( click the link to review the publication )

Int J Neuropsychopharmacol, 2016, 10.1093/ijnp/pyw035

PubMed: 27207921 ( click the link to review the publication )

Int J Oncol, 2016, 49(6):2453-2463

PubMed: 27748897 ( click the link to review the publication )

Am J Physiol Heart Circ Physiol, 2016, 311(5):H1139-H1149

PubMed: 27638876 ( click the link to review the publication )
Oncol Rep, 2016, 36(4):1875-85

PubMed: 27509880 ( click the link to review the publication )

Biochem Biophys Res Commun, 2016, 474(1):71-75

PubMed: 27091426 ( click the link to review the publication )

Leuk Res, 2016, 47:100-8

PubMed: 27294334 ( click the link to review the publication )

Target Oncol, 2016, 11(6):783-798

PubMed: 27250763 ( click the link to review the publication )

Oncotarget, 2016, 10.18632/oncotarget.8379

PubMed: 27028869 ( click the link to review the publication )

Oncotarget, 2016, 7(4):4454-67

PubMed: 26683357 ( click the link to review the publication )

Nat Commun, 2015, 3;6:10091

PubMed: 26631872 ( click the link to review the publication )

Clin Cancer Res, 2015, 10.1158/1078-0432.CCR-14-1561

PubMed: ( click the link to review the publication )

Leukemia, 2015, 29(3):556-66

PubMed: 25118879 ( click the link to review the publication )

Clin Cancer Res, 2015, 21(7):1628-38

PubMed: 25623213 ( click the link to review the publication )

Blood Cancer J, 2015, 5:e357

PubMed: 26473529 ( click the link to review the publication )

Endocr Relat Cancer, 2015, 22(5):777-92

PubMed: 26206775 ( click the link to review the publication )

Epigenetics, 2015, 10.1080/15592294.2015.1039216

PubMed: 25923331 ( click the link to review the publication )

Antimicrob Agents Chemother, 2015, 59(7):3984-94

PubMed: 25896701 ( click the link to review the publication )

Sci Rep, 2015, 5:16445

PubMed: 26563568 ( click the link to review the publication )

J Biol Chem, 2015, 290(39):23725-37

PubMed: 26269591 ( click the link to review the publication )

J Biol Chem, 2015, 290(8):5028-40

PubMed: 25540204 ( click the link to review the publication )

J Biol Chem, 2015, 290(8):5028-40

PubMed: ( click the link to review the publication )

Int J Parasitol Drugs Drug Resist, 2015, 5(3):117-26

PubMed: 26199860 ( click the link to review the publication )

PLoS One, 2015, 10(12):e0145994

PubMed: 26717578 ( click the link to review the publication )

Tumour Biol, 2015, 36(7):5485-95

PubMed: 26036758 ( click the link to review the publication )

Clin Cancer Res, 2014, 10.1158/1078-0432.CCR-14-0384

PubMed: 25355930 ( click the link to review the publication )

Diabetes, 2014, 63(9):2924-34

PubMed: 24722245 ( click the link to review the publication )

PLoS Pathog, 2014, 10(8):e1004287

PubMed: 25122219 ( click the link to review the publication )
Cell Death Dis, 2014, 5:e1134

PubMed: 24651437 ( click the link to review the publication )

Mol Cell Biol, 2014, 34(7):1280-9

PubMed: 24469401 ( click the link to review the publication )

J Chem Inf Model, 2014, 10.1002/ijc.28924

PubMed: 24771510 ( click the link to review the publication )

J Neurosci, 2013, 33(17):7535-47

PubMed: 23616558 ( click the link to review the publication )

Mol Cancer Ther, 2013, 12(8):1591-604

PubMed: 23536727 ( click the link to review the publication )

Br J Haematol, 2013, 162(4):559-62

PubMed: 23692150 ( click the link to review the publication )

Purity & Quality Control

Choose Selective HDAC Inhibitors

Biological Activity

Description

Features

More effective than other classical HDAC inhibitors such as TSA, TPX, and butyrate.

Targets

HDAC1 ^[1] (Cell-free assay)	HDAC2 ^[1] (Cell-free assay)
36 nM	47 nM

In vitro

Unlike TSA, the active form redFK of Romidepsin strongly inhibits HDAC1 and HDAC2 with IC50 of 1.6 nM and 3.9 nM, respectively, but is relatively weak in inhibiting HDAC4 and HDAC6 with IC50 25 nM and 790 nM, respectively. Romidepsin is 17-23 times weaker than redFK in inhibiting these HDACs with IC50 of 36 nM, 47 nM, 510 nM, and 14 μM, respectively. Romidepsin treatment in HeLa cells induces histone acetylation and p21 expression with EC50 of 3.0 nM, more strongly than redFK with EC50 of 11 nM due to the instability of redFK. ^[1] In addition to G2/M arrest, Romidepsin treatment causes cyclin D1 downregulation and a p53-independent p21 induction, leading to inhibition of CDK and dephosphorylation of Rb resulting in growth arrest in the early G1 phase. ^[2] Romidepsin is 100 times more potent than TSA and 1,000,000 times more potent than butyrate in inhibiting the proliferation of the A549 cells. ^[3] Romidepsin inhibits the growth of U-937, K562, and CCRF-CEM cells with IC50 of 5.92 nM, 8.36 nM, and 6.95 nM, respectively. ^[5] Romidepsin promotes apoptosis in chronic lymphocytic leukemia (CLL) cells at a concentration corresponding to that at which H3 and H4 acetylation and HDAC inhibition occurs, selectively involving activation of caspase 8 and effector caspase 3, as well as down-regulation of c-FLIP protein. ^[6] In 11 of 13 (85%) renal cell carcinoma cell lines and in 16 of 37 (43%) other cancer cell lines, Romidepsin treatment up-regulates tumor death receptors, and potentiates natural killer (NK)-mediated tumor killing. ^[7] Romidepsin exhibits concentration-dependent cytotoxicity against a panel of mantle cell lymphoma (MCL) cell lines. ^[9]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
SU-DHL4	NXLl[FRjS2WubDDWbYFjcWyrdImgRZN{[Xl?	M2DGelIvPS1zNTDuUS=>	MW[3NkBp		MYXpcoR2[2W\|IHP5eI91d3irY3n0fUBqdiCjIHPvcoNmdnS{YYTpc44u\GWyZX7k[Y51KG2jbn7lduKh	MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTd7MEmwO{c,OjV5OUC5NFc9N2F-
U2932	NX3KdFZ7S2WubDDWbYFjcWyrdImgRZN{[Xl?	NHX0T5ozNjVvMUWgcm0>	NYC0cWY1PzJiaB?=		NUPuRlJRcW6mdXPld{BkgXSxdH;4bYNqfHliaX6gZUBkd26lZX70doF1cW:wLXTldIVv\GWwdDDtZY5v\XMEoB?=	NVjKN2Y3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW3PVA6ODdpPkK1O\|kxQTB5PD;hQi=>
OCI-LY7	M1zsRWNmdGxiVnnhZoltcXS7IFHzd4F6	NIfIU5EzNjVvMUWgcm0>	NFK2UYI4OiCq		NVXmWY1QcW6mdXPld{BkgXSxdH;4bYNqfHliaX6gZUBkd26lZX70doF1cW:wLXTldIVv\GWwdDDtZY5v\XMEoB?=	MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTd7MEmwO{c,OjV5OUC5NFc9N2F-
Farage	NXvEd45HS2WubDDWbYFjcWyrdImgRZN{[Xl?	NGe0e4kzNjVvMUWgcm0>	M4LJbFczKGh?		MlnXbY5lfWOnczDjfZRwfG:6aXPpeJkhcW5iYTDjc45k\W62cnH0bY9vNWSncHXu[IVvfCCvYX7u[ZLDqA>?	MnfDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5OUC5NFcoRjJ3N{mwPVA4RC:jPh?=
LY7/EBV	MlX0R4VtdCCYaXHibYxqfHliQYPzZZk>	NILPeFYzNjVvMUWgcm0>	NEK2eJA4OiCq		NIH3NWdqdmS3Y3XzJIN6fG:2b4jpZ4l1gSCrbjDhJINwdmOnboTyZZRqd25vZHXw[Y5l\W62IH3hco5mesLi	MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTd7MEmwO{c,OjV5OUC5NFc9N2F-
U2932/EBV	NFexVm1E\WyuIG\pZYJqdGm2eTDBd5NigQ>?	NVLnRXZqOi53LUG1JI5O	MlLiO\|IhcA>?		M2q1b4lv\HWlZYOgZ5l1d3SxeHnjbZR6KGmwIHGgZ49v[2WwdILheIlwdi2mZYDlcoRmdnRibXHucoVzyqB?	NFHrW5Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUe5NFkxPyd-MkW3PVA6ODd:L3G+
HCT116	NH\IXG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEDuOIo2NTVyMECgcm0>	NETIb\|YzPCCq	NHzxcJpFVVOR	MVLpcoR2[2W\|IHPlcIwh\GWjdHigbY4h[SClb37j[Y51emG2aX;uMYRmeGWwZHXueEBu[W6wZYK=	MkPCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV2OUK1NVUoRjJ3NEmyOVE2RC:jPh?=
ACH-2	MVHGeY5kfGmxbjDBd5NigQ>?	MVSxMVkhdk1?	MVuyOEBp		MXfpcoR2[2W\|IFjJWk0yKEWwdjDlfJBz\XO\|aX;u	MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTF2OUS2O{c,OjVzNEm0Olc9N2F-
MCF-10A	NHLuOG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmC1TWM2OD1yLkG3xtExNjBzIH7N	MnLIQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7NUS4OVYoRjJ2OUW0PFU3RC:jPh?=
MCF-7	NXXYTnE{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYTVb45DUUN3ME2xMlExyrFyLkKwJI5O	NHjNNFc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEm1OFg2Pid-MkS5OVQ5PTZ:L3G+
SK-BR-3	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYnqPXZvUUN3ME2xMlAxyrFyLkO1JI5O	NYTCNpFSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5OVQ5PTZpPkK0PVU1QDV4PD;hQi=>
MDA-MB-231	M4W4WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2\sPGlEPTB;MD62POKyOC5zNDDuUS=>	MlT5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7NUS4OVYoRjJ2OUW0PFU3RC:jPh?=
PC3	NFe2TFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4fXd2lEPTB;MT62OeKyOC5\|NTDuUS=>	MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDl3NEi1Okc,OjR7NUS4OVY9N2F-
HCT116	M{K2U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlrITWM2OD1zLkCwxtExNjByIH7N	M1nKc\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUW0PFU3Lz5{NEm1OFg2PjxxYU6=
HCT116-p21-/-	NG\xRm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NU\CTmlrUUN3ME2xMlI3yrFyLkO3JI5O	M2TBO\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUW0PFU3Lz5{NEm1OFg2PjxxYU6=
S1	M1\VcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVTJR\|UxRTdwNkhCtVAvOjlibl2=	MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDl3NEi1Okc,OjR7NUS4OVY9N2F-
SW620	M37iUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFvPeotKSzVyPUCuPVPDuTBwMkmgcm0>	MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDl3NEi1Okc,OjR7NUS4OVY9N2F-
LOX-IMVI	NYPQSFIxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHGwSW9KSzVyPUCuPFfDuTBwMEOgcm0>	M2\6XlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUW0PFU3Lz5{NEm1OFg2PjxxYU6=
UACC-62	NGToOYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmfhTWM2OD1yLkW2xtExNjF4IH7N	Ml64QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7NUS4OVYoRjJ2OUW0PFU3RC:jPh?=
MDA-MB-435	M{PIUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2fDPWlEPTB;MD65NOKyOC5yNjDuUS=>	NWL3cG5KRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5OVQ5PTZpPkK0PVU1QDV4PD;hQi=>
SF-295	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mon3TWM2OD1yLki4xtExNjF3IH7N	M{DBUFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUW0PFU3Lz5{NEm1OFg2PjxxYU6=
A549	Mn7tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXrJR\|UxRTFwMkdCtVAvOjRibl2=	Mn7SQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7NUS4OVYoRjJ2OUW0PFU3RC:jPh?=
H460	MoDQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHXFTG1KSzVyPUKuOVjDuTBwOECgcm0>	NH24TXQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEm1OFg2Pid-MkS5OVQ5PTZ:L3G+
EKVX	M3j1UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NF74[W1KSzVyPUGuN\|PDuTBwM{Sgcm0>	M1zvW\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUW0PFU3Lz5{NEm1OFg2PjxxYU6=
H146	MmfvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVTJR\|UxRTBwMkNCtVAvODdibl2=	Mkn0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7NUS4OVYoRjJ2OUW0PFU3RC:jPh?=
H526	M3jSd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGPxZ4dKSzVyPUCuNVXDuTBwMEOgcm0>	MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDl3NEi1Okc,OjR7NUS4OVY9N2F-
HuT-78	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3u5R2lEPTB;MT63N:KyOC52NDDuUS=>	NY\wd201RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5OVQ5PTZpPkK0PVU1QDV4PD;hQi=>
HA	NUHONXQxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEDuWYExNjZ{NT2xNI5O	NYTzWmYyPDhiaB?=		NWGxXFFUcW6mdXPld{BiKHOrZ37p[olk[W62bImgd5Rzd26pZYKgbY5pcWKrdHnvckBw\iClZXzsJJBzd2yrZnXyZZRqd25iY3:teJJm[XSnZDD3bZRpKGKxcoTlfo9ucWJ?	NWDpVogzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS3O\|E2OTBpPkK0O\|cyPTFyPD;hQi=>
MS-275	NV:w[WhRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWKwMlYzPS1zMH7N	MoG2OFghcA>?		NUfGfWVPcW6mdXPld{BiKHOrZ37p[olk[W62bImgd5Rzd26pZYKgbY5pcWKrdHnvckBw\iClZXzsJJBzd2yrZnXyZZRqd25iY3:teJJm[XSnZDD3bZRpKGKxcoTlfo9ucWJ?	MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDd5MUWxNEc,OjR5N{G1NVA9N2F-
CD4 T	M{jXO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M2WyTVQ5KGh?		MYnFR\|UxRTRwNdMxNU4xKG6P	M4rje\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2N{KyOFU1Lz5{NEeyNlQ2PDxxYU6=
CD4 T	MlSyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NYm2WVdnPDhiaB?=		NHvBfGJESzVyPUGwO:KyOTJ4IH7N	M1jRNlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2N{KyOFU1Lz5{NEeyNlQ2PDxxYU6=
CD4+ T	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWrFR\|UxRTNibl2=	NX[yb4NIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS0PVUyODVpPkK0OFk2OTB3PD;hQi=>
A549	MlTiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NF:4NFQyOOLCk{GwNOKhdk1?	NHrROHIzPC9\|Nj:0PEBp		MWrpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCkb4ToJINwdmOnboTyZZRqd25vIHHu[EB1cW2nLXTldIVv\GWwdDDtZY5v\XJ?	MmT3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR2OEW3PVkoRjJ2NEi1O\|k6RC:jPh?=
JJN3	M3nm[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		Mn62NlQwPDhiaB?=		NYLPV\|hJTUN3MEyx5qCKdk19IES45qCKcA>?	Mo\RQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRyM{CxOVAoRjJ2MEOwNVUxRC:jPh?=
OPM-2	NEXwN\|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NWP0XFlWOjRxNEigbC=>		MV3FR\|Uxez1z4pEJcm08KDR64pEJbC=>	M{fqfFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MEOwNVUxLz5{NECzNFE2ODxxYU6=
RPMI-8226	MmrZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NV\nXJM6OjRxNEigbC=>		MUnFR\|Uxez1zLklihKlvVTtiNElihKlp	NFzZR449[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NECzNFE2OCd-MkSwN\|AyPTB:L3G+
U266	MnywS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NHPxdm4zPC92ODDo		NXf3U\|QzTUN3MIO9NVDjiImwTUugOFjjiImq	NH3zPYU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NECzNFE2OCd-MkSwN\|AyPTB:L3G+
CA46	MlTRRZBweHSxc3nzJGF{e2G7		NXXDclNMPiCq		NVO0cpl1cW6mdXPld{BjdHWwdDDhdI9xfG:\|aYO=	M{Hhd\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OU[2NVY1Lz5{M{m2OlE3PDxxYU6=
DG75	NIDXb2lCeG:ydH;zbZMhSXO\|YYm=		M1foT\|YhcA>?		NXnJRXJwcW6mdXPld{BvdyCjcH;weI9{cXN?	NVPoT2tQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO5OlYyPjRpPkKzPVY3OTZ2PD;hQi=>
Ramos	NV7DT4p2SXCxcITvd4l{KEG\|c3H5		NGW2V\|M3KGh?		MkTrbY5lfWOnczDlfJRmdnOrdnWgZZBweHSxc3nz	NVfH[2JbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO5OlYyPjRpPkKzPVY3OTZ2PD;hQi=>
ST486	M4i2OmFxd3C2b4Ppd{BCe3OjeR?=		MnXyOkBp		NX7Id2ljcW6mdXPld{BmgHSnboPpeoUh[XCxcITvd4l{	Ml3QQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN7Nk[xOlQoRjJ\|OU[2NVY1RC:jPh?=
HuT78	NEDPVG5CeG:ydH;zbZMhSXO\|YYm=	M3ToRlEwOTBxMUCwJI5O	MYO0PEBp		NWW1b3JFcW6mdXPld{BieG:ydH;zbZMh[XRiMTDuUS=>	MkHSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN3M{K3N\|IoRjJ\|NUOyO\|MzRC:jPh?=
DpVp35	MljYRZBweHSxc3nzJGF{e2G7	NWjuclg4OS9zMD:xNFAhdk1?	NGfsOGQ1QCCq		NXvmblVqcW6mdXPld{BjdHWwdDDhdI9xfG:\|aYO=	MnTKQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN3M{K3N\|IoRjJ\|NUOyO\|MzRC:jPh?=
DpVp50	NYjQ[G1[SXCxcITvd4l{KEG\|c3H5	NYnXT5NMOS9zMD:xNFAhdk1?	MVW0PEBp		MnjpbY5lfWOnczDicJVvfCCjcH;weI9{cXN?	Mm[2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN3M{K3N\|IoRjJ\|NUOyO\|MzRC:jPh?=
DpP75	M2jRXWFxd3C2b4Ppd{BCe3OjeR?=	MVixM\|ExNzFyMDDuUS=>	M1nY[VQ5KGh?		M1L1Solv\HWlZYOgZox2dnRiYYDvdJRwe2m\|	NUfiWGJMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO1N\|I4OzJpPkKzOVMzPzN{PD;hQi=>
SKOV-3	M1HBVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4jZRlHjiJN{MH7N	Mnq3O\|IhcA>?	M4D2[2ROW09?	MofndoVlfWOnczDj[YxtKH[rYXLpcIl1gSCjbH;u[UBidmRiY3;tZolv\WRid3n0bEBkcXOybHH0bY4>	MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzBzMEO0PEc,OjNyMUCzOFg9N2F-
Brca1 WT	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4CySlHjiJN{MH7N	NYXrUYZyPzJiaB?=	MnfRSG1UVw>?	NGXZ[2Vz\WS3Y3XzJINmdGxidnnhZoltcXS7IHHsc45mKGGwZDDjc41jcW6nZDD3bZRpKGOrc4DsZZRqdg>?	M33KRVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|MEGwN\|Q5Lz5{M{CxNFM1QDxxYU6=
Brca1 Null	Ml;DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXOx5qCUOjCwTR?=	NULVWlRsPzJiaB?=	MmTPSG1UVw>?	MmftdoVlfWOnczDj[YxtKH[rYXLpcIl1gSCjbH;u[UBidmRiY3;tZolv\WRid3n0bEBkcXOybHH0bY4>	NXT4bVQ4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOwNVA{PDhpPkKzNFExOzR6PD;hQi=>
OVCAR-8	MkHzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV3mbodbOeLCk{Kwcm0>	NY\WfGpDPzJiaB?=	MV3EUXNQ	NFXrXXVz\WS3Y3XzJINmdGxidnnhZoltcXS7IHHsc45mKGGwZDDjc41jcW6nZDD3bZRpKGOrc4DsZZRqdg>?	MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzBzMEO0PEc,OjNyMUCzOFg9N2F-
NCI/ADR-RES	MoX6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWqx5qCUOjCwTR?=	M2TJVlczKGh?	M3O2d2ROW09?	NFjIdHJz\WS3Y3XzJINmdGxidnnhZoltcXS7IHHsc45mKGGwZDDjc41jcW6nZDD3bZRpKGOrc4DsZZRqdg>?	NX\4T\|B5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOwNVA{PDhpPkKzNFExOzR6PD;hQi=>
HCT116	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVm1JI5ONTVyIN88US=>	M2jj[\|I1KGh?	MkjTSG1UVw>?	M4jNV4lvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGgZ49v[2WwdILheIlwdi2mZYDlcoRmdnRibXHucoVz	NVi3SotGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK5NlQ6PThpPkKyPVI1QTV6PD;hQi=>
RKO	NHWweIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXzqUGJsPSCwTT21NEDPxE1?	MUeyOEBp	NYewPHFJTE2VTx?=	M4X1dYlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGgZ49v[2WwdILheIlwdi2mZYDlcoRmdnRibXHucoVz	NVuzfWN2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK5NlQ6PThpPkKyPVI1QTV6PD;hQi=>
CO115	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkfiOUBvVS13MDFOwG0>	MWmyOEBp	MWfEUXNQ	M3\4[YlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGgZ49v[2WwdILheIlwdi2mZYDlcoRmdnRibXHucoVz	NEfW[Yg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkmyOFk2QCd-MkK5NlQ6PTh:L3G+
HFS	NHj6ZXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYW1JI5O	MlXXNlQwPDhxN{KgbC=>		NHz5N2RqdmirYnn0d{Bk\WyuIHfyc5d1cCC2aX3lMYRmeGWwZHXueIx6	MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjFyNkK4Nkc,OjJzME[yPFI9N2F-
LNCaP	M1G4Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUO1JI5O	MoqwNlQwPDhxN{KgbC=>		MYTpcohq[mm2czDj[YxtKGe{b4f0bEB1cW2nLXTldIVv\GWwdHz5	MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjFyNkK4Nkc,OjJzME[yPFI9N2F-
A549	M{nqZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFuyTZg2KG6P	MYiyOE81QC95MjDo		M4nzfYlvcGmkaYTzJINmdGxiZ4Lve5RpKHSrbXWt[IVx\W6mZX70cJk>	MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjFyNkK4Nkc,OjJzME[yPFI9N2F-
697	M{TSZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUL0Oo9MUUN3MPMAjV3jiIl{LkZCpI5O	MoPwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF3M{iyNVYoRjJzNUO4NlE3RC:jPh?=
697-R	NUf0d406T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXrJR\|Ux6oDLPfMAjVgvPsLibl5CpC=>	NF\4bmc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUWzPFIyPid-MkG1N\|gzOTZ:L3G+
HUT78	MnTJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEe0VHVKSzVyPUGgcm0>	MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTF7OEW0OUc,OjFzOUi1OFU9N2F-
THJ-16T	NXjZZ\|dRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NH\JcHQyKG6P	MoX0NlQhcA>?		M{P1[4lvcGmkaYTzJINmdGxiZ4Lve5Rp	MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODhzMEW2PEc,OjB6MUC1Olg9N2F-
HCT116	NIPSfo5HfW6ldHnvckBCe3OjeR?=	NV;1b3M2OjBibl2=	NFTSe5E5KGh?		NIfjR3Nud2S3bHH0[ZMhfHKjboPjdolxfCCuZY\lcJMh\m:{IHj1coRz\WS\|IH;mJIdmdmW\|IHnuJIVqfGincjDkbZJm[3Srb36=	MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODd\|OUS1OEc,OjB5M{m0OVQ9N2F-
B104	NHLsR3JHfW6ldHnvckBCe3OjeR?=	NUi3NYtmOiCwTR?=	MmfJNlQwPDhxN{KgbC=>		M1jtUIlv[3KnYYPld{B1cGVic4Xy[oFk\SCneIDy[ZN{cW:wIH;mJGNFOjEEoB?=	NX7B[41lRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkC2PFY2ODVpPkKwOlg3PTB3PD;hQi=>
HL-60	NGTveYNEgXSxdH;4bYNqfHliQYPzZZk>	MY[xMVUxOCCwTR?=	M1zrOFI1KGh?		M17wSYlv\HWlZYOgZ5l1d3SxeHnjbZR6KGmwIHGgZ49v[2WwdILheIlwdi2mZYDlcoRmdnRibXHucoVzyqB?	NYTQXIxDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkC2NlQyPjNpPkKwOlI1OTZ\|PD;hQi=>
HP100	NEn5XVBEgXSxdH;4bYNqfHliQYPzZZk>	M2PTc\|EuPTByIH7N	NIDK[IgzPCCq		NWD3V3J5cW6mdXPld{BkgXSxdH;4bYNqfHliaX6gZUBkd26lZX70doF1cW:wLXTldIVv\GWwdDDtZY5v\XMEoB?=	NIiyUIU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{ME[yOFE3Oyd-MkC2NlQyPjN:L3G+
HL-60	NVnpRmk6TnWwY4Tpc44hSXO\|YYm=	NV;XTlhjOTBibl2=	NVvCWXg5PC94L{G2JIg>		MWPpcoR2[2W\|IITo[UBo\W6ncnH0bY9vKG:oIHj5[JJw\2WwIIDldo95cWSnIH\yc40hPGh?	NH;odY09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{ME[yOFE3Oyd-MkC2NlQyPjN:L3G+
HP100	NFTve\|lHfW6ldHnvckBCe3OjeR?=	NV73NlA6OTBibl2=	MXO0M\|YwOTZiaB?=		NXz0ZnlUcW6mdXPld{B1cGViZ3Xu[ZJifGmxbjDv[kBpgWS{b3flckBx\XKxeHnk[UBnem:vIETo	NGHvSHM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{ME[yOFE3Oyd-MkC2NlQyPjN:L3G+
HL-60	MorFSpVv[3Srb36gRZN{[Xl?	MYexNE02ODBibl2=	MlzJOEBp		NFTqdmhl\WO{ZXHz[ZMhfGinIHjpd5RwdmViZHXhZ4V1gWyjc3WgLGhFSUNrIHHjeIl3cXS7wrC=	MkTGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB4MkSxOlMoRjJyNkK0NVY{RC:jPh?=
HP100	MVfGeY5kfGmxbjDBd5NigQ>?	NG\IO48yOC13MECgcm0>	MV:0JIg>		MlfP[IVkemWjc3XzJJRp\SCqaYP0c45mKGSnYXPleJlt[XOnIDjISGFEMSCjY4Tpeol1gcLi	MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODZ{NEG2N{c,OjB4MkSxOlM9N2F-
11z	M4DlTGtqdmG\|ZTDBd5NigQ>?	M17OVFMuOTByIH7N			MVvy[YR2[2W\|IFjERWMh\W68eX3heIlkKGGldHn2bZR6KCiLQ{WwxsA:KDZwNTFCtUAxNjZibn3vcE9NMQ>?	MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODZyNUG0OEc,OjB4MEWxOFQ9N2F-
SKOV-3	NWCxRYdFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIPiR4M1NzhxMU[gcm0>	MnXwOFghcA>?		M3u1U4lvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGgZ49v[2WwdILheIlwdi2mZYDlcoRmdnRibXHucoVz	MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODRyNEW2OEc,OjB2MES1OlQ9N2F-
OVCAR-3	NW\uWIZWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVe0M\|gwOTZibl2=	MV[0PEBp		M3L3TYlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGgZ49v[2WwdILheIlwdi2mZYDlcoRmdnRibXHucoVz	NHq2fHA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MESwOFU3PCd-MkC0NFQ2PjR:L3G+
HBL-2	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYXSeGY{Oi1zMDDuUS=>	NX3xT29oOjRiaB?=		NILscJFKSzVyPUSuN{BvVQ>?	M1LqflxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyME[4NFgxLz5{MEC2PFA5ODxxYU6=
Jeko-1	MnnyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MX[yMVUxKG6P	Mlf6NlQhcA>?		MmDRTWM2OD1zMTDuUS=>	MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODB4OEC4NEc,OjByNkiwPFA9N2F-
Granta-519	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEjRU4Q2NTRyIH7N	MUOyOEBp		Ml\ZTWM2OD13OD61JI5O	MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODB4OEC4NEc,OjByNkiwPFA9N2F-
L1236	NVmzeWZWS3m2b4TvfIlkcXS7IFHzd4F6	Mm\MNUBvVS1zMECg{txO	NHH2WYk1QCCq		M4TwcmVEPTB;MD6wO{DPxE1?	M3vHPVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7MkOzOFcxLz5zOUKzN\|Q4ODxxYU6=
L428	M1[3N2N6fG:2b4jpZ4l1gSCDc4PhfS=>	NFLJcpkyKG6PLUGwNEDPxE1?	MWq0PEBp		M3LZNWVEPTB;MD60N{DPxE1?	M1PVVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7MkOzOFcxLz5zOUKzN\|Q4ODxxYU6=
KM-H2	NHf0N2xEgXSxdH;4bYNqfHliQYPzZZk>	NEnqb4oyKG6PLUGwNEDPxE1?	MY[0PEBp		M33aWmVEPTB;MD61PEDPxE1?	NEXDPWM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUKzN\|Q4OCd-MUmyN\|M1PzB:L3G+
L540Cy	M{\4ZmN6fG:2b4jpZ4l1gSCDc4PhfS=>	Mn7jNUBvVS1zMECg{txO	NXLLO2prPDhiaB?=		M4HZWWVEPTB;MD6xOkDPxE1?	M{P4ZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7MkOzOFcxLz5zOUKzN\|Q4ODxxYU6=
G401	NXy1N\|R5TnWwY4Tpc44hSXO\|YYm=	MlnFNVAhdk1?	NW\z[mRNOjRxNEivO\|IhcA>?	NXT2S2UxTE2VTx?=	MV;pcoNz\WG\|ZYOgR2RMVjGFIHX4dJJme3Orb36=	NFG0W5k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUKyNVU5Pid-MUmyNlE2QDZ:L3G+
STM91-01	NUDxWnhuTnWwY4Tpc44hSXO\|YYm=	M1jPSFExKG6P	NXj6[olKOjRxNEivO\|IhcA>?	NFXDZotFVVOR	Mo\kbY5kemWjc3XzJGNFU05zQzDlfJBz\XO\|aX;u	MoXyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl{MkG1PFYoRjF7MkKxOVg3RC:jPh?=
SJSC	NUewdmJKTnWwY4Tpc44hSXO\|YYm=	MoK0NVAhdk1?	M1[3OFI1NzR6L{eyJIg>	MUnEUXNQ	MUnpcoNz\WG\|ZYOgR2RMVjGFIHX4dJJme3Orb36=	NH[xe2E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUKyNVU5Pid-MUmyNlE2QDZ:L3G+
BT16	M1i2ZmZ2dmO2aX;uJGF{e2G7	NFvHZ2QyOCCwTR?=	NVLDcFFHOjRxNEivO\|IhcA>?	MojVSG1UVw>?	M33WOolv[3KnYYPld{BETEuQMVOg[ZhxemW\|c3nvci=>	NUXRSpZxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUmyNlE2QDZpPkG5NlIyPTh4PD;hQi=>
NCI-H1299	MorWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmPrTWM2OD12LkdCtVAvOiCwZz;tcC=>	NGPtRY89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUG3PVg6OCd-MUmxO\|k5QTB:L3G+
NCI-2882	Mn3qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUHXe4JPUUN3ME2xMlbDuTBwMESgcocwdWx?	MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTF5OUi5NEc,OTlzN{m4PVA9N2F-
HCC95	MnPXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVXJR\|UxRTJwNdMxNE4xPSCwZz;tcC=>	MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTF5OUi5NEc,OTlzN{m4PVA9N2F-
NCI-H23	NXPkZ5p6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYnvUXk2UUN3ME2yMlnDuTBwMjDu[{9udA>?	NYfXcpJKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUmxO\|k5QTBpPkG5NVc6QDlyPD;hQi=>
NCI-H157	MmHtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{nuOWlEPTB;MT62xtExNjB{IH7nM41t	NYrwR2h4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUmxO\|k5QTBpPkG5NVc6QDlyPD;hQi=>
NCI-H460	M3nqd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4P6fWlEPTB;Mj6xxtExNjB5IH7nM41t	M4TEWFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7MUe5PFkxLz5zOUG3PVg6ODxxYU6=
NCI-H1975	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVTWfnhSUUN3ME2xMlPDuTBwMESgcocwdWx?	NI\2TXk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUG3PVg6OCd-MUmxO\|k5QTB:L3G+
NCI-H820	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NH\5e4dKSzVyPUKuOOKyOC5zIH7nM41t	NEHrRZU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUG3PVg6OCd-MUmxO\|k5QTB:L3G+
NCI-H1650	M4ewVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlfiTWM2OD12LkpCtVAvOyCwZz;tcC=>	NYrPd\|ZNRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUmxO\|k5QTBpPkG5NVc6QDlyPD;hQi=>
DTC1	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1\6WWlEPTB;MD61NUBvVQ>?	NHflSGM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEW2OlI1Pid-MUi1OlYzPDZ:L3G+
KAO	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGnvUmNKSzVyPUCuPVEhdk1?	M4\TUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6NU[2NlQ3Lz5zOEW2OlI1PjxxYU6=
SU-CCS-1	NXLYPGpDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUi5WGVHUUN3ME2wMlg6KG6P	MmSyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh3Nk[yOFYoRjF6NU[2NlQ3RC:jPh?=
SYO-1	NHToPVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2jmRmlEPTB;MD62O{BvVQ>?	Mn23QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh3Nk[yOFYoRjF6NU[2NlQ3RC:jPh?=
FUJI	MkjwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MojoTWM2OD1zLkOxJI5O	MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDV4NkK0Okc,OTh3Nk[yOFY9N2F-
SKNMC	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mnu2TWM2OD1zLkG3JI5O	M3HNWFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6NU[2NlQ3Lz5zOEW2OlI1PjxxYU6=
402-91	M1HQcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmrkTWM2OD1zLkK2JI5O	NVv5UFVqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi1OlYzPDZpPkG4OVY3OjR4PD;hQi=>
1765-92	M{nIU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2rOR2lEPTB;MT63O{BvVQ>?	M33r[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6NU[2NlQ3Lz5zOEW2OlI1PjxxYU6=
JN-DSRCT-1	Mlf1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGfFXHRKSzVyPUGuNlUhdk1?	NF3HdoY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEW2OlI1Pid-MUi1OlYzPDZ:L3G+
NMS-2PC	M2HCe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MX\JR\|UxRTBwOEGgcm0>	NWi1TIZTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi1OlYzPDZpPkG4OVY3OjR4PD;hQi=>
HL60	NUnCRoJ1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MV;JR\|UxRTFwOE[gcm0>	Mo[3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh3Nk[yOFYoRjF6NU[2NlQ3RC:jPh?=
A549	NWHv[o8yT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NF3pO\|ZKSzVyPUOuNlQhdk1?	M2W4S\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6NU[2NlQ3Lz5zOEW2OlI1PjxxYU6=
SW480	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mn;ZTWM2OD1{Lk[5JI5O	MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDV4NkK0Okc,OTh3Nk[yOFY9N2F-
MCF7	MmTkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4HuVGlEPTB;Mz61OUBvVQ>?	MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDV4NkK0Okc,OTh3Nk[yOFY9N2F-
PC-3	NYrrbIV4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVzJR\|UxRTJwNUGgcm0>	MmfzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh3Nk[yOFYoRjF6NU[2NlQ3RC:jPh?=
MMRU	NUn6UpM1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmLKTWM2OD1{LkW3JI5O	MkLiQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh3Nk[yOFYoRjF6NU[2NlQ3RC:jPh?=
Hs68	M3LCcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mmj5TWM2OD1-MUCgcm0>	MkXNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh3Nk[yOFYoRjF6NU[2NlQ3RC:jPh?=
hMSC-001F	MlfGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NH;ONotKSzVyPU6xNEBvVQ>?	M37r[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6NU[2NlQ3Lz5zOEW2OlI1PjxxYU6=
mammalian cells	MmTxSpVv[3Srb36gZZN{[Xl?				MY\Jcohq[mm2aX;uJI9nKEirc4TvcoUh\GWjY3X0fYxie2ViNDDpckBu[W2vYXzpZY4h[2WubIOsJGlEPTBiPTCwMlUyKM7:TT6=	M1O4[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF2NUi0PVMzLz5zNEW4OFk{OjxxYU6=
mammalian cells	MYTGeY5kfGmxbjDhd5NigQ>?				MkW0TY5pcWKrdHnvckBw\iCKaYP0c45mKGSnYXPleJlt[XOnIEGgbY5lfWOnZDDhZ4V1gWyjdHXkJIhqe3SxbnWgbY4hdWGvbXHsbYFvKGOnbHzzMkwhTUN3MDC9JFM3KM7:TT6=	NXTYV2RZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUS1PFQ6OzJpPkG0OVg1QTN{PD;hQi=>
MCF7	NIW2N4xIem:5dHigbY5pcWKrdHnvckBie3OjeR?=				MYPHdo94fGhiaX7obYJqfGmxbjDv[kBOS0Z5IHPlcIx{NCCLQ{WwJF0hOC5yMEC3OUDPxE1w	MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzl3OEO0Nkc,OTd7NUizOFI9N2F-
A498	NU\aWGh[S3m2b4TvfIlkcXS7IHHzd4F6		MXi2JIRigXN?		NIfJXVlEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBCPDl6IHPlcIx{KGGodHXyJFYh\GG7czDifUBOXFRiYYPzZZktKFSJSTC9JFAvODJ6IN88UU4>	Mo\DQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF7NkexOFYoRjJzOU[3NVQ3RC:jPh?=
COLO205	MmfSR5l1d3SxeHnjbZR6KGG\|c3H5		MmjiOkBl[Xm\|		M{G2ZmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGNQVE9{MEWgZ4VtdHNiYX\0[ZIhPiCmYYnzJIJ6KE2WVDDhd5NigSxiVFfJJF0hOC5yM{Gg{txONg>?	NHjLdWI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUm2O\|E1Pid-MkG5OlcyPDZ:L3G+
U251	MWLDfZRwfG:6aXPpeJkh[XO\|YYm=		NVPJcYtxPiCmYYnz		M3fPcmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJHUzPTFiY3XscJMh[W[2ZYKgOkBl[Xm\|IHL5JG1VXCCjc4PhfUwhXEeLIE2gNE4xOzFizszNMi=>	MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTl4N{G0Okc,OjF7NkexOFY9N2F-
RXF393	NH[5dW1EgXSxdH;4bYNqfHliYYPzZZk>		MX22JIRigXN?		M174RWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJHJZTjN7MzDj[YxteyCjZoTldkA3KGSjeYOgZpkhVVSWIHHzd4F6NCCWR1mgQUAxNjB4MjFOwG0v	MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTl4N{G0Okc,OjF7NkexOFY9N2F-
MDA-MB-468	MoS0R5l1d3SxeHnjbZR6KGG\|c3H5		M3exeFYh\GG7cx?=		MoH2R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUWRCNU2ELUS2PEBk\WyuczDh[pRmeiB4IHThfZMh[nliTWTUJIF{e2G7LDDUS2khRSByLkC5JO69VS5?	MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTl4N{G0Okc,OjF7NkexOFY9N2F-
COLO205	NY\McVhCS3m2b4TvfIlkcXS7IHHzd4F6		MWK2JIRigXN?		NIXOc5VEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBEV0yRMkC1JINmdGy\|IHHmeIVzKDZiZHH5d{BjgSCPVGSgZZN{[XluIFzDOVAhRSByLkC5NkDPxE1w	MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTl4N{G0Okc,OjF7NkexOFY9N2F-
UACC257	MXPDfZRwfG:6aXPpeJkh[XO\|YYm=		NWPBdY9MPiCmYYnz		NIrESGZEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBWSUOFMkW3JINmdGy\|IHHmeIVzKDZiZHH5d{BjgSCPVGSgZZN{[XluIGTHTUA:KDBwMEm1JO69VS5?	NETrRXc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUm2O\|E1Pid-MkG5OlcyPDZ:L3G+
U251	NGjZcJdEgXSxdH;4bYNqfHliYYPzZZk>		MVq2JIRigXN?		NHjhV2ZEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBWOjVzIHPlcIx{KGGodHXyJFYh\GG7czDifUBOXFRiYYPzZZktKEyFNUCgQUAxNjF\|IN88UU4>	MlqxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF7NkexOFYoRjJzOU[3NVQ3RC:jPh?=
A498	MX7DfZRwfG:6aXPpeJkh[XO\|YYm=		NIfQOJY3KGSjeYO=		M2HhUmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGE1QThiY3XscJMh[W[2ZYKgOkBl[Xm\|IHL5JG1VXCCjc4PhfUwhVEN3MDC9JFAvOiEQvF2u	M2jPZ\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzOU[3NVQ3Lz5{MUm2O\|E1PjxxYU6=
NCI-H322M	MoT3R5l1d3SxeHnjbZR6KGG\|c3H5		NUHkZolnPiCmYYnz		NVTKXHg3S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVkOLLVizNlJOKGOnbHzzJIFnfGW{IE[g[IF6eyCkeTDNWHQh[XO\|YYmsJHRIUSB;IECuNlMh\|ryPLh?=	MlL3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF7NkexOFYoRjJzOU[3NVQ3RC:jPh?=
SF295	MoPtR5l1d3SxeHnjbZR6KGG\|c3H5		NHfPPFU3KGSjeYO=		NHnafohEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBUTjJ7NTDj[YxteyCjZoTldkA3KGSjeYOgZpkhVVSWIHHzd4F6NCCWR1mgQUAxNjJ3IN88UU4>	M2[3T\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzOU[3NVQ3Lz5{MUm2O\|E1PjxxYU6=
RXF393	MkPIR5l1d3SxeHnjbZR6KGG\|c3H5		M2e3ZlYh\GG7cx?=		Ml\BR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gVnhHOzl\|IHPlcIx{KGGodHXyJFYh\GG7czDifUBOXFRiYYPzZZktKEyFNUCgQUAxNjNizszNMi=>	MoPMQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF7NkexOFYoRjJzOU[3NVQ3RC:jPh?=
NCI60	M4L5dmN6fG:2b4jpZ4l1gSCjc4PhfS=>		M{LEc\|Yh\GG7cx?=		MX7DfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDOR2k3OCClZXzsd{Bi\nSncjC2JIRigXNiYomgUXRVKGG\|c3H5MEBVT0liPTCwMlM{KM7:TT6=	MmntQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF7NkexOFYoRjJzOU[3NVQ3RC:jPh?=
SN12C	M1exWGN6fG:2b4jpZ4l1gSCjc4PhfS=>		MoXXOkBl[Xm\|		M3HmcmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJHNPOTKFIHPlcIx{KGGodHXyJFYh\GG7czDifUBOXFRiYYPzZZktKFSJSTC9JFAvOzRizszNMi=>	MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTl4N{G0Okc,OjF7NkexOFY9N2F-
MDA-MB-231	NGLjeVJEgXSxdH;4bYNqfHliYYPzZZk>		M2e0T\|Yh\GG7cx?=		MlX3R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUWRCNU2ELUKzNUBk\WyuczDh[pRmeiB4IHThfZMh[nliTWTUJIF{e2G7LDDUS2khRSByLkO1JO69VS5?	Mkf3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF7NkexOFYoRjJzOU[3NVQ3RC:jPh?=
ACHN	MVTDfZRwfG:6aXPpeJkh[XO\|YYm=		M4rzUFYh\GG7cx?=		NFrkeWREgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBCS0iQIHPlcIx{KGGodHXyJFYh\GG7czDifUBOXFRiYYPzZZktKFSJSTC9JFAvPzNizszNMi=>	NHjvcZo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUm2O\|E1Pid-MkG5OlcyPDZ:L3G+
SN12C	MYrDfZRwfG:6aXPpeJkh[XO\|YYm=		NGjkfIQ3KGSjeYO=		NWjaT3BwS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hW05zMlOgZ4VtdHNiYX\0[ZIhPiCmYYnzJIJ6KE2WVDDhd5NigSxiTFO1NEA:KDFwNTFOwG0v	NUXXXVd4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG5OlcyPDZpPkKxPVY4OTR4PD;hQi=>
UO31	NVfCS\|hQS3m2b4TvfIlkcXS7IHHzd4F6		NY\QSW5vPiCmYYnz		NETRSW9EgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBWVzNzIHPlcIx{KGGodHXyJFYh\GG7czDifUBOXFRiYYPzZZktKFSJSTC9JFEvPTVizszNMi=>	MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTl4N{G0Okc,OjF7NkexOFY9N2F-
Caki1	M3vNVmN6fG:2b4jpZ4l1gSCjc4PhfS=>		M2P1[\|Yh\GG7cx?=		NWXkTI5GS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hS2GtaUGgZ4VtdHNiYX\0[ZIhPiCmYYnzJIJ6KE2WVDDhd5NigSxiVFfJJF0hOS56OTFOwG0v	MkezQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF7NkexOFYoRjJzOU[3NVQ3RC:jPh?=
NCI60	M4e4[WN6fG:2b4jpZ4l1gSCjc4PhfS=>		NH\ZcYw3KGSjeYO=		MXTDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDOR2k3OCClZXzsd{Bi\nSncjC2JIRigXNiYomgUXRVKGG\|c3H5MEBNSzVyIE2gN{42KM7:TT6=	NH\kO3c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUm2O\|E1Pid-MkG5OlcyPDZ:L3G+
MDA-MB-231	MoPWR5l1d3SxeHnjbZR6KGG\|c3H5		MWS2JIRigXN?		NYrQUVZ3S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVUSDLV3CMVI{OSClZXzsd{Bi\nSncjC2JIRigXNiYomgUXRVKGG\|c3H5MEBNSzVyIE2gOE4xQCEQvF2u	NGTSXXY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUm2O\|E1Pid-MkG5OlcyPDZ:L3G+
MDA-MB-468	M4\scmN6fG:2b4jpZ4l1gSCjc4PhfS=>		NIHwV\|g3KGSjeYO=		NHnFSFBEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBOTEFvTVKtOFY5KGOnbHzzJIFnfGW{IE[g[IF6eyCkeTDNWHQh[XO\|YYmsJGxEPTBiPTC0MlE1KM7:TT6=	NVn0SWNxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG5OlcyPDZpPkKxPVY4OTR4PD;hQi=>
ACHN	NET0NZFEgXSxdH;4bYNqfHliYYPzZZk>		NE\EXVE3KGSjeYO=		MV7DfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDBR2hPKGOnbHzzJIFnfGW{IE[g[IF6eyCkeTDNWHQh[XO\|YYmsJGxEPTBiPTC1MlM4KM7:TT6=	Ml\mQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF7NkexOFYoRjJzOU[3NVQ3RC:jPh?=
UACC257	MXTDfZRwfG:6aXPpeJkh[XO\|YYm=		NHvLTnQ3KGSjeYO=		NYDnVIVsS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hXUGFQ{K1O{Bk\WyuczDh[pRmeiB4IHThfZMh[nliTWTUJIF{e2G7LDDMR\|UxKD1iNT60OkDPxE1w	M2HrXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzOU[3NVQ3Lz5{MUm2O\|E1PjxxYU6=
NCI-H322M	MYLDfZRwfG:6aXPpeJkh[XO\|YYm=		NYS0bVQxPiCmYYnz		NXzaZ2NlS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVkOLLVizNlJOKGOnbHzzJIFnfGW{IE[g[IF6eyCkeTDNWHQh[XO\|YYmsJGxEPTBiPTC5MlAzKM7:TT6=	MlHSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF7NkexOFYoRjJzOU[3NVQ3RC:jPh?=
SF295	NVPrVVVYS3m2b4TvfIlkcXS7IHHzd4F6		NH3UOZA3KGSjeYO=		MXzDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDTSlI6PSClZXzsd{Bi\nSncjC2JIRigXNiYomgUXRVKGG\|c3H5MEBNSzVyIE2gNVAvOiEQvF2u	Ml\UQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF7NkexOFYoRjJzOU[3NVQ3RC:jPh?=
Caki1	NYT2dFF1S3m2b4TvfIlkcXS7IHHzd4F6		NHvsTIs3KGSjeYO=		M1qwZmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGNic2lzIHPlcIx{KGGodHXyJFYh\GG7czDifUBOXFRiYYPzZZktKEyFNUCgQUAzOC57IN88UU4>	NFPuOXE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUm2O\|E1Pid-MkG5OlcyPDZ:L3G+
NCI-H23	NY\3eJN[SW62aYT1cY9zKGG\|c3H5	NYHj[o5tOS54IITvJFIvPCCvZz;r[y=>	NYK5XYRufXBidH:gOUBl[Xm\|		MV\BcpRqfHWvb4KgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCQQ1mtTFI{KGOnbHzzJIlueGyjboTl[EBqdnS{YYDldol1d26nYXzsfUBqdiCvb4Xz[UBie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJJR2dW:{IHPlcIwh\3Kxd4ToJIF1KDFwNjD0c{AzNjRibXevb4ctKGmyIHHkcYlvcXO2ZYLl[EBwdiCmYYmgNUB1dyB2IH3lZZN2emWmIH;uJIRigSB3IHL5JIhwdGyxdzDmbYJmeiCjc4PhfS=>	M2HuT\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzOU[3NVQ3Lz5{MUm2O\|E1PjxxYU6=
NCI-H522	NFywXlJCdnSrdIXtc5Ih[XO\|YYm=	NXfUSFk{OS54IITvJFIvPCCvZz;r[y=>	NVy5WXlCfXBidH:gOUBl[Xm\|		MYjBcpRqfHWvb4KgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCQQ1mtTFUzOiClZXzsd{BqdXCuYX70[YQhcW62cnHw[ZJqfG:wZXHscJkhcW5ibX;1d4Uh[XO\|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kB1fW2xcjDj[YxtKGe{b4f0bEBifCBzLk[geI8hOi52IH3nM4toNCCrcDDh[I1qdmm\|dHXy[YQhd25iZHH5JFEhfG9iNDDt[YF{fXKnZDDvckBl[XliNTDifUBpd2yub4eg[olj\XJiYYPzZZk>	MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTl4N{G0Okc,OjF7NkexOFY9N2F-
OVCAR5	NWHSclBGSW62aYT1cY9zKGG\|c3H5	NV75VohXOS54IITvJFIvPCCvZz;r[y=>	NFjDSHR2eCC2bzC1JIRigXN?		MlG2RY51cXS3bX;yJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iT2\DRXI2KGOnbHzzJIlueGyjboTl[EBqdnS{YYDldol1d26nYXzsfUBqdiCvb4Xz[UBie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJJR2dW:{IHPlcIwh\3Kxd4ToJIF1KDFwNjD0c{AzNjRibXevb4ctKGmyIHHkcYlvcXO2ZYLl[EBwdiCmYYmgNUB1dyB2IH3lZZN2emWmIH;uJIRigSB3IHL5JIhwdGyxdzDmbYJmeiCjc4PhfS=>	Mm[3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF7NkexOFYoRjJzOU[3NVQ3RC:jPh?=
SW620	NIjIdHBCdnSrdIXtc5Ih[XO\|YYm=	MWSxMlYhfG9iMj60JI1oN2up	MV31dEB1dyB3IHThfZM>		NEPUXXdCdnSrdIXtc5Ih[WO2aY\peJkh[WejaX7zeEBpfW2jbjDTW\|YzOCClZXzsd{BqdXCuYX70[YQhcW62cnHw[ZJqfG:wZXHscJkhcW5ibX;1d4Uh[XO\|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kB1fW2xcjDj[YxtKGe{b4f0bEBifCBzLk[geI8hOi52IH3nM4toNCCrcDDh[I1qdmm\|dHXy[YQhd25iZHH5JFEhfG9iNDDt[YF{fXKnZDDvckBl[XliNTDifUBpd2yub4eg[olj\XJiYYPzZZk>	MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTl4N{G0Okc,OjF7NkexOFY9N2F-
MDA-MB-435	MmDaRY51cXS3bX;yJIF{e2G7	Mkj3NU43KHSxIEKuOEBu\y:tZx?=	MYT1dEB1dyB3IHThfZM>		NUX6U5l1SW62aYT1cY9zKGGldHn2bZR6KGGpYXnud5QhcHWvYX6gUWRCNU2ELUSzOUBk\WyuczDpcZBt[W62ZXSgbY51emGyZYLpeI9v\WGubImgbY4hdW:3c3WgZZN{\XO\|ZXSgZZMhcW6qaXLpeIlwdiCxZjD0eY1weiClZXzsJIdzd3e2aDDheEAyNjZidH:gNk41KG2pL3vnMEBqeCCjZH3pcol{fGW{ZXSgc44h\GG7IEGgeI8hPCCvZXHzeZJm\CCxbjDkZZkhPSCkeTDoc4xtd3diZnni[ZIh[XO\|YYm=	MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTl4N{G0Okc,OjF7NkexOFY9N2F-
COLO205	MWDBcpRqfHWvb4KgZZN{[Xl?	MVuxMlYhfG9iMj60JI1oN2up	MoTJeZAhfG9iNTDkZZl{		M3vHOWFvfGm2dX3vdkBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFPPUG8zODViY3XscJMhcW2ybHHueIVlKGmwdILhdIVzcXSxbnXhcIx6KGmwIH3veZNmKGG\|c3Xzd4VlKGG\|IHnubIljcXSrb36gc4YhfHWvb4KgZ4VtdCCpcn;3eIgh[XRiMT62JJRwKDJwNDDt[{9s\yxiaYCgZYRucW6rc4TldoVlKG:wIHThfUAyKHSxIESgcYVie3W{ZXSgc44h\GG7IEWgZpkhcG:ubH;3JIZq[mW{IHHzd4F6	NWfTOoV6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG5OlcyPDZpPkKxPVY4OTR4PD;hQi=>
LOXIMVI	NHfpXY9CdnSrdIXtc5Ih[XO\|YYm=	NHP4SlgyNjZidH:gNk41KG2pL3vn	Ml3HeZAhfG9iNTDkZZl{		M4XzUGFvfGm2dX3vdkBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFzPXGlOXkliY3XscJMhcW2ybHHueIVlKGmwdILhdIVzcXSxbnXhcIx6KGmwIH3veZNmKGG\|c3Xzd4VlKGG\|IHnubIljcXSrb36gc4YhfHWvb4KgZ4VtdCCpcn;3eIgh[XRiMT62JJRwKDJwNDDt[{9s\yxiaYCgZYRucW6rc4TldoVlKG:wIHThfUAyKHSxIESgcYVie3W{ZXSgc44h\GG7IEWgZpkhcG:ubH;3JIZq[mW{IHHzd4F6	MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTl4N{G0Okc,OjF7NkexOFY9N2F-
UACC62	MXrBcpRqfHWvb4KgZZN{[Xl?	NXXhXFJWOS54IITvJFIvPCCvZz;r[y=>	MkLQeZAhfG9iNTDkZZl{		NEmxSGRCdnSrdIXtc5Ih[WO2aY\peJkh[WejaX7zeEBpfW2jbjDVRWNEPjJiY3XscJMhcW2ybHHueIVlKGmwdILhdIVzcXSxbnXhcIx6KGmwIH3veZNmKGG\|c3Xzd4VlKGG\|IHnubIljcXSrb36gc4YhfHWvb4KgZ4VtdCCpcn;3eIgh[XRiMT62JJRwKDJwNDDt[{9s\yxiaYCgZYRucW6rc4TldoVlKG:wIHThfUAyKHSxIESgcYVie3W{ZXSgc44h\GG7IEWgZpkhcG:ubH;3JIZq[mW{IHHzd4F6	MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTl4N{G0Okc,OjF7NkexOFY9N2F-
MDA-MB-231	M{npPGFvfGm2dX3vdkBie3OjeR?=	M3LpU\|EvPiC2bzCyMlQhdWdxa3e=	MnjNeZAhfG9iNTDkZZl{		MX\BcpRqfHWvb4KgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCPRFGtUWIuOjNzIHPlcIx{KGmvcHzhcpRm\CCrboTyZZBmemm2b37lZYxtgSCrbjDtc5V{\SCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKHS3bX;yJINmdGxiZ4Lve5RpKGG2IEGuOkB1dyB{LkSgcYcwc2duIHnwJIFldWmwaYP0[ZJm\CCxbjDkZZkhOSC2bzC0JI1m[XO3cnXkJI9vKGSjeTC1JIJ6KGixbHzve{BncWKncjDhd5NigQ>?	MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTl4N{G0Okc,OjF7NkexOFY9N2F-
SF295	MUTBcpRqfHWvb4KgZZN{[Xl?	M1;PU\|EvPiC2bzCyMlQhdWdxa3e=	NUCyWmkzfXBidH:gOUBl[Xm\|		NIPIcZZCdnSrdIXtc5Ih[WO2aY\peJkh[WejaX7zeEBpfW2jbjDTSlI6PSClZXzsd{BqdXCuYX70[YQhcW62cnHw[ZJqfG:wZXHscJkhcW5ibX;1d4Uh[XO\|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kB1fW2xcjDj[YxtKGe{b4f0bEBifCBzLk[geI8hOi52IH3nM4toNCCrcDDh[I1qdmm\|dHXy[YQhd25iZHH5JFEhfG9iNDDt[YF{fXKnZDDvckBl[XliNTDifUBpd2yub4eg[olj\XJiYYPzZZk>	MoLEQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF7NkexOFYoRjJzOU[3NVQ3RC:jPh?=
U251	MXHBcpRqfHWvb4KgZZN{[Xl?	MlXYNU43KHSxIEKuOEBu\y:tZx?=	M{O3cJVxKHSxIEWg[IF6ew>?		NEjrO4RCdnSrdIXtc5Ih[WO2aY\peJkh[WejaX7zeEBpfW2jbjDVNlUyKGOnbHzzJIlueGyjboTl[EBqdnS{YYDldol1d26nYXzsfUBqdiCvb4Xz[UBie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJJR2dW:{IHPlcIwh\3Kxd4ToJIF1KDFwNjD0c{AzNjRibXevb4ctKGmyIHHkcYlvcXO2ZYLl[EBwdiCmYYmgNUB1dyB2IH3lZZN2emWmIH;uJIRigSB3IHL5JIhwdGyxdzDmbYJmeiCjc4PhfS=>	MkTuQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF7NkexOFYoRjJzOU[3NVQ3RC:jPh?=
OVRAC3	MUjBcpRqfHWvb4KgZZN{[Xl?	MXyxMlYhfG9iMj60JI1oN2up	NH\PN3V2eCC2bzC1JIRigXN?		MX\BcpRqfHWvb4KgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCRVmLBR\|Mh[2WubIOgbY1xdGGwdHXkJIlvfHKjcHXybZRwdmWjbHz5JIlvKG2xdYPlJIF{e2W\|c3XkJIF{KGmwaHnibZRqd25ib3[geJVud3JiY3XscEBoem:5dHigZZQhOS54IITvJFIvPCCvZz;r[{whcXBiYXTtbY5qe3SncnXkJI9vKGSjeTCxJJRwKDRibXXhd5Vz\WRib36g[IF6KDViYomgbI9tdG:5IH\pZoVzKGG\|c3H5	NVLXdppQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG5OlcyPDZpPkKxPVY4OTR4PD;hQi=>
LLC	NGPq[4tHfW6ldHnvckBie3OjeR?=				NIDJZnZKdmirYnn0bY9vKG:oIFjERWMudWWmaXH0[YQhUEmILUHhcJBp[SCjY4Tpeol1gSCrbjDtc5V{\SCOTFOgZ4VtdHNuIFnDOVAhRSB{IN88UU4>	NGnaXnM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkOwOVYyOid-MkKzNFU3OTJ:L3G+
NCI-H522	M2fS[Gdzd3e2aDDpcohq[mm2aX;uJIF{e2G7				NWPpfYVGT3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLVi1NlIh[2WubIOgZpkhe3WuZn;ybI9l[W2rbnWgRkBkd2yxcnnt[ZRzcWNibXX0bI9lNCCJSUWwJF0hOC5yMEG4JO69VS5?	MknVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN\|MUO2N\|goRjJ\|M{GzOlM5RC:jPh?=
LOXIMVI	M3;ndWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7				NXrGeZF7T3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hVE:[SV3WTUBk\WyuczDifUB{fWyob4Loc4RidWmwZTDCJINwdG:{aX3leJJq[yCvZYToc4QtKEeLNUCgQUAxNjByMkWg{txONg>?	NHjqU5Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{OxN\|Y{QCd-MkOzNVM3Ozh:L3G+
A549	MVPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?				NF;4e3FIem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBCPTR7IHPlcIx{KGK7IIP1cIZwemixZHHtbY5mKEJiY3;sc5JqdWW2cnnjJI1mfGixZDygS2k2OCB;IECuNFAzPiEQvF2u	NGHaPG89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{OxN\|Y{QCd-MkOzNVM3Ozh:L3G+
OVCAR5	NHHjWIhIem:5dHigbY5pcWKrdHnvckBie3OjeR?=				NHHtblFIem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBQXkODUkWgZ4VtdHNiYomgd5Vt\m:{aH;kZY1qdmViQjDjc4xwemmvZYTybYMhdWW2aH;kMEBIUTVyIE2gNE4xODJ6IN88UU4>	MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzNzM{[zPEc,OjN\|MUO2N\|g9N2F-
MKN74	M1S4b2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7				M3Xmdmdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJG1MVjd2IHPlcIx{KGK7IIP1cIZwemixZHHtbY5mKEJiY3;sc5JqdWW2cnnjJI1mfGixZDygS2k2OCB;IECuNFA{KM7:TT6=	MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzNzM{[zPEc,OjN\|MUO2N\|g9N2F-
NCI-H460	MYXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?				NELsR2tIem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSES2NEBk\WyuczDifUB{fWyob4Loc4RidWmwZTDCJINwdG:{aX3leJJq[yCvZYToc4QtKEeLNUCgQUAxNjByMzFOwG0v	NVLse49ZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOzNVM3OzhpPkKzN\|E{PjN6PD;hQi=>
HCT116	NEjJOYJIem:5dHigbY5pcWKrdHnvckBie3OjeR?=				M2LNcGdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJGhEXDFzNjDj[YxteyCkeTDzeYxnd3Kqb3ThcYlv\SCEIHPvcI9zcW2ndILpZ{Bu\XSqb3SsJGdKPTBiPTCwMlAxOzFizszNMi=>	NUjxOGdWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOzNVM3OzhpPkKzN\|E{PjN6PD;hQi=>
HCC2998	MX;Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?				MVvHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDIR2MzQTl6IHPlcIx{KGK7IIP1cIZwemixZHHtbY5mKEJiY3;sc5JqdWW2cnnjJI1mfGixZDygS2k2OCB;IECuNFA{OSEQvF2u	NH\KUWU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{OxN\|Y{QCd-MkOzNVM3Ozh:L3G+
MKN1	NXzRelRqT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=				MYHHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDNT24yKGOnbHzzJIJ6KHO3bH\vdohw\GGvaX7lJGIh[2:ub4LpcYV1emmlIH3leIhw\CxiR1m1NEA:KDBwMECzNkDPxE1w	NYD3eYhMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOzNVM3OzhpPkKzN\|E{PjN6PD;hQi=>
SKOV3	M{D5fmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7				M17W[Gdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJHNMV1Z\|IHPlcIx{KGK7IIP1cIZwemixZHHtbY5mKEJiY3;sc5JqdWW2cnnjJI1mfGixZDygS2k2OCB;IECuNFA{OyEQvF2u	M{\reFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|M{GzOlM5Lz5{M{OxN\|Y{QDxxYU6=
HT-29	MoO5S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?				NYDHT\|FxT3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hUFRvMkmgZ4VtdHNiYomgd5Vt\m:{aH;kZY1qdmViQjDjc4xwemmvZYTybYMhdWW2aH;kMEBIUTVyIE2gNE4xODN\|IN88UU4>	NHHq[HA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{OxN\|Y{QCd-MkOzNVM3Ozh:L3G+
KM12	M1rqPWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7				MmrOS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gT20yOiClZXzsd{BjgSC\|dXzmc5Jpd2SjbXnu[UBDKGOxbH;ybY1mfHKrYzDt[ZRpd2RuIFfJOVAhRSByLkCwN\|Qh\|ryPLh?=	MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzNzM{[zPEc,OjN\|MUO2N\|g9N2F-
DMS114	MU\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?				NFv2NphIem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBFVVNzMUSgZ4VtdHNiYomgd5Vt\m:{aH;kZY1qdmViQjDjc4xwemmvZYTybYMhdWW2aH;kMEBIUTVyIE2gNE4xODN4IN88UU4>	MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzNzM{[zPEc,OjN\|MUO2N\|g9N2F-
SF539	NEPWcYRIem:5dHigbY5pcWKrdHnvckBie3OjeR?=				M1jEcmdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJHNHPTN7IHPlcIx{KGK7IIP1cIZwemixZHHtbY5mKEJiY3;sc5JqdWW2cnnjJI1mfGixZDygS2k2OCB;IECuNFA{PiEQvF2u	MoS0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN\|MUO2N\|goRjJ\|M{GzOlM5RC:jPh?=
U251	M{jIemdzd3e2aDDpcohq[mm2aX;uJIF{e2G7				NV7zUoo5T3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hXTJ3MTDj[YxteyCkeTDzeYxnd3Kqb3ThcYlv\SCEIHPvcI9zcW2ndILpZ{Bu\XSqb3SsJGdKPTBiPTCwMlAxOzlizszNMi=>	MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzNzM{[zPEc,OjN\|MUO2N\|g9N2F-
SF295	NVPoNmo5T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=				MmftS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gV2YzQTViY3XscJMh[nlic4Xs[o9zcG:mYX3pcoUhSiClb3zvdolu\XS{aXOgcYV1cG:mLDDHTVUxKD1iMD6wNFQh\|ryPLh?=	NYPve4RuRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOzNVM3OzhpPkKzN\|E{PjN6PD;hQi=>
MCF7	MWXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?				NFfxe41Iem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBOS0Z5IHPlcIx{KGK7IIP1cIZwemixZHHtbY5mKEJiY3;sc5JqdWW2cnnjJI1mfGixZDygS2k2OCB;IECuNFA1OiEQvF2u	MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzNzM{[zPEc,OjN\|MUO2N\|g9N2F-
NCI-H23	NEjwOppIem:5dHigbY5pcWKrdHnvckBie3OjeR?=				MXHHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDOR2kuUDJ\|IHPlcIx{KGK7IIP1cIZwemixZHHtbY5mKEJiY3;sc5JqdWW2cnnjJI1mfGixZDygS2k2OCB;IECuNFA1PiEQvF2u	MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzNzM{[zPEc,OjN\|MUO2N\|g9N2F-
OVCAR3	MnHxS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?				NWnB[W1[T3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hV1[FQWKzJINmdGy\|IHL5JJN2dG[xcnjv[IFucW6nIFKgZ49td3KrbXX0dolkKG2ndHjv[EwhT0l3MDC9JFAvODB2NjFOwG0v	M1HsZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|M{GzOlM5Lz5{M{OxN\|Y{QDxxYU6=
MKN7	MnvVS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?				MYDHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDNT244KGOnbHzzJIJ6KHO3bH\vdohw\GGvaX7lJGIh[2:ub4LpcYV1emmlIH3leIhw\CxiR1m1NEA:KDBwMEC0PUDPxE1w	NVnSRnNTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOzNVM3OzhpPkKzN\|E{PjN6PD;hQi=>
SF268	NHjFVIRIem:5dHigbY5pcWKrdHnvckBie3OjeR?=				M1nubGdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJHNHOjZ6IHPlcIx{KGK7IIP1cIZwemixZHHtbY5mKEJiY3;sc5JqdWW2cnnjJI1mfGixZDygS2k2OCB;IECuNFA1QSEQvF2u	NFXvW2c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{OxN\|Y{QCd-MkOzNVM3Ozh:L3G+
MDA-MB-231	NYnmS4l7T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=				MUnHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDNSGEuVUJvMkOxJINmdGy\|IHL5JJN2dG[xcnjv[IFucW6nIFKgZ49td3KrbXX0dolkKG2ndHjv[EwhT0l3MDC9JFAvODB3NTFOwG0v	NFXyT2w9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{OxN\|Y{QCd-MkOzNVM3Ozh:L3G+
OVCAR8	M3:5OGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7				M{e5R2dzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJG9XS0GUODDj[YxteyCkeTDzeYxnd3Kqb3ThcYlv\SCEIHPvcI9zcW2ndILpZ{Bu\XSqb3SsJGdKPTBiPTCwMlAxPTVizszNMi=>	NHLz[HE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{OxN\|Y{QCd-MkOzNVM3Ozh:L3G+
DMS273	NWHQd\|k1T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=				M4fr[mdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJGROWzJ5MzDj[YxteyCkeTDzeYxnd3Kqb3ThcYlv\SCEIHPvcI9zcW2ndILpZ{Bu\XSqb3SsJGdKPTBiPTCwMlAxPThizszNMi=>	M3nXXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|M{GzOlM5Lz5{M{OxN\|Y{QDxxYU6=
DU145	Mn:1S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?				MXrHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDEWVE1PSClZXzsd{BjgSC\|dXzmc5Jpd2SjbXnu[UBDKGOxbH;ybY1mfHKrYzDt[ZRpd2RuIFfJOVAhRSByLkCwOkDPxE1w	MkHLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN\|MUO2N\|goRjJ\|M{GzOlM5RC:jPh?=
RXF631L	M4nWSWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7				NXjKc3pCT3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hWliINkOxUEBk\WyuczDifUB{fWyob4Loc4RidWmwZTDCJINwdG:{aX3leJJq[yCvZYToc4QtKEeLNUCgQUAxNjByNk[g{txONg>?	NH74[ZY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{OxN\|Y{QCd-MkOzNVM3Ozh:L3G+
HBC4	MmXVS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?				NH3aOWVIem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBJSkN2IHPlcIx{KGK7IIP1cIZwemixZHHtbY5mKEJiY3;sc5JqdWW2cnnjJI1mfGixZDygS2k2OCB;IECuNFA3QSEQvF2u	MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzNzM{[zPEc,OjN\|MUO2N\|g9N2F-
SNB75	NHTrcFVIem:5dHigbY5pcWKrdHnvckBie3OjeR?=				MXTHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDTUmI4PSClZXzsd{BjgSC\|dXzmc5Jpd2SjbXnu[UBDKGOxbH;ybY1mfHKrYzDt[ZRpd2RuIFfJOVAhRSByLkCwO\|Ih\|ryPLh?=	NES3WpE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{OxN\|Y{QCd-MkOzNVM3Ozh:L3G+
BSY1	MnHyS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?				M2nSUWdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJGJUYTFiY3XscJMh[nlic4Xs[o9zcG:mYX3pcoUhSiClb3zvdolu\XS{aXOgcYV1cG:mLDDHTVUxKD1iMD6wNFg2KM7:TT6=	NXLER4lDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOzNVM3OzhpPkKzN\|E{PjN6PD;hQi=>
NCI-H226	MUnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?				M3mwWWdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KMkK2JINmdGy\|IHL5JJN2dG[xcnjv[IFucW6nIFKgZ49td3KrbXX0dolkKG2ndHjv[EwhT0l3MDC9JFAvODB6OTFOwG0v	NILEWXA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{OxN\|Y{QCd-MkOzNVM3Ozh:L3G+
SNB78	NEOzdXdIem:5dHigbY5pcWKrdHnvckBie3OjeR?=				M3yzO2dzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJHNPSjd6IHPlcIx{KGK7IIP1cIZwemixZHHtbY5mKEJiY3;sc5JqdWW2cnnjJI1mfGixZDygS2k2OCB;IECuNFA6PiEQvF2u	NX7DO\|JHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOzNVM3OzhpPkKzN\|E{PjN6PD;hQi=>
HBC5	MULHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?				NH3CSpFIem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBJSkN3IHPlcIx{KGK7IIP1cIZwemixZHHtbY5mKEJiY3;sc5JqdWW2cnnjJI1mfGixZDygS2k2OCB;IECuNFE{KM7:TT6=	MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzNzM{[zPEc,OjN\|MUO2N\|g9N2F-
MKN45	MlXuS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?				MkDXS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gUWtPPDViY3XscJMh[nlic4Xs[o9zcG:mYX3pcoUhSiClb3zvdolu\XS{aXOgcYV1cG:mLDDHTVUxKD1iMD6wNVQh\|ryPLh?=	NHf1Z\|U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{OxN\|Y{QCd-MkOzNVM3Ozh:L3G+
MKN28	NVzOTGpzT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=				NH7ncY5Iem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBOU05{ODDj[YxteyCkeTDzeYxnd3Kqb3ThcYlv\SCEIHPvcI9zcW2ndILpZ{Bu\XSqb3SsJGdKPTBiPTCwMlAyPyEQvF2u	M2HPXVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|M{GzOlM5Lz5{M{OxN\|Y{QDxxYU6=
PC3	NF7IZ4tIem:5dHigbY5pcWKrdHnvckBie3OjeR?=				NWHEbplzT3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hWEN\|IHPlcIx{KGK7IIP1cIZwemixZHHtbY5mKEJiY3;sc5JqdWW2cnnjJI1mfGixZDygS2k2OCB;IECuNFE5KM7:TT6=	MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzNzM{[zPEc,OjN\|MUO2N\|g9N2F-
ACHN	Mk\TS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?				M1XIUmdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJGFEUE5iY3XscJMh[nlic4Xs[o9zcG:mYX3pcoUhSiClb3zvdolu\XS{aXOgcYV1cG:mLDDHTVUxKD1iMD6wNkDPxE1w	M1POTlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|M{GzOlM5Lz5{M{OxN\|Y{QDxxYU6=
OVCAR4	NELLN2NIem:5dHigbY5pcWKrdHnvckBie3OjeR?=				NX3pW\|V7T3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hV1[FQWK0JINmdGy\|IHL5JJN2dG[xcnjv[IFucW6nIFKgZ49td3KrbXX0dolkKG2ndHjv[EwhT0l3MDC9JFAvODJizszNMi=>	NYfkRmJIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOzNVM3OzhpPkKzN\|E{PjN6PD;hQi=>
St-4	NHnVVY1Iem:5dHigbY5pcWKrdHnvckBie3OjeR?=				MlKyS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gV5QuPCClZXzsd{BjgSC\|dXzmc5Jpd2SjbXnu[UBDKGOxbH;ybY1mfHKrYzDt[ZRpd2RuIFfJOVAhRSByLkCyNkDPxE1w	NYjGboFERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOzNVM3OzhpPkKzN\|E{PjN6PD;hQi=>
HCT15	MYDHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?				MUTHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDIR3QyPSClZXzsd{BjgSC\|dXzmc5Jpd2SjbXnu[UBDKGOxbH;ybY1mfHKrYzDt[ZRpd2RuIFfJOVAhRSByLkS1JO69VS5?	Ml[zQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN\|MUO2N\|goRjJ\|M{GzOlM5RC:jPh?=
CD4+ T	NFq1SVZHfW6ldHnvckBie3OjeR?=		M2HFcFch\GG7cx?=		NWLzWJA4WmWjY4TpeoF1cW:wIH;mJIxifGWwdDDITXYyKE6OND2zMWx2[yCneIDy[ZN{cW:wIHnuJIh2dWGwIH7hbZZmKEOGNDugWEBk\WyuczD0doVifGWmIEeg[IF6eyCyb4P0MYlv\mWldHnvckBu\WG\|dYLl[EBi\nSncjC0PEBpenNiYomgcJVucW6nc3PlcoNmKHCuYYTlJJJm[WSncjDhcoFtgXOrczygSWM2OCB;IECuNFA{KM7:TT6=	M32xZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NEm1NVA2Lz5{NES5OVExPTxxYU6=
NCI-H522	M2LrbWN6fG:2b4jpZ4l1gSCjc4PhfS=>				M3njOWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG5EUS2KNUKyJINmdGy\|IHL5JHNTSiCjc4PhfUwhT0l3MDC9JFAvODBzODFOwG0v	Mk[0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR3OEm0PFYoRjJ2NUi5OFg3RC:jPh?=
LOXIMVI	NHvDRY1EgXSxdH;4bYNqfHliYYPzZZk>				NIPwTHdEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBNV1iLTW\JJINmdGy\|IHL5JHNTSiCjc4PhfUwhT0l3MDC9JFAvODB{NTFOwG0v	NX7hbokzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS1PFk1QDZpPkK0OVg6PDh4PD;hQi=>
A549	NHq2fItEgXSxdH;4bYNqfHliYYPzZZk>				MVfDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDBOVQ6KGOnbHzzJIJ6KFOUQjDhd5NigSxiR1m1NEA:KDBwMECyOkDPxE1w	MmPSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR3OEm0PFYoRjJ2NUi5OFg3RC:jPh?=
OVCAR5	MV\DfZRwfG:6aXPpeJkh[XO\|YYm=				NF7tS\|ZEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBQXkODUkWgZ4VtdHNiYomgV3JDKGG\|c3H5MEBIUTVyIE2gNE4xODJ6IN88UU4>	MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDV6OUS4Okc,OjR3OEm0PFY9N2F-
NCI-H460	NH;sfVJEgXSxdH;4bYNqfHliYYPzZZk>				NHXSPGxEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBPS0lvSES2NEBk\WyuczDifUBUWkJiYYPzZZktKEeLNUCgQUAxNjByMzFOwG0v	M3XYXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NUi5OFg3Lz5{NEW4PVQ5PjxxYU6=
MKN74	M1i2TWN6fG:2b4jpZ4l1gSCjc4PhfS=>				NV[xVIZ5S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVUuQN{SgZ4VtdHNiYomgV3JDKGG\|c3H5MEBIUTVyIE2gNE4xODNizszNMi=>	M1fCfVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NUi5OFg3Lz5{NEW4PVQ5PjxxYU6=
HCC2998	MWXDfZRwfG:6aXPpeJkh[XO\|YYm=				MU\DfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDIR2MzQTl6IHPlcIx{KGK7IGPSRkBie3OjeTygS2k2OCB;IECuNFA{OSEQvF2u	NYLw[HliRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS1PFk1QDZpPkK0OVg6PDh4PD;hQi=>
HCT116	NXzEWJloS3m2b4TvfIlkcXS7IHHzd4F6				M{j3VGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGhEXDFzNjDj[YxteyCkeTDTVmIh[XO\|YYmsJGdKPTBiPTCwMlAxOzFizszNMi=>	NI\MWVk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEW4PVQ5Pid-MkS1PFk1QDZ:L3G+
MKN1	M2W0W2N6fG:2b4jpZ4l1gSCjc4PhfS=>				MUnDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDNT24yKGOnbHzzJIJ6KFOUQjDhd5NigSxiR1m1NEA:KDBwMECzNkDPxE1w	Mkj5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR3OEm0PFYoRjJ2NUi5OFg3RC:jPh?=
HT-29	M4L5[2N6fG:2b4jpZ4l1gSCjc4PhfS=>				MVPDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDIWE0zQSClZXzsd{BjgSCVUlKgZZN{[XluIFfJOVAhRSByLkCwN\|Mh\|ryPLh?=	MlmxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR3OEm0PFYoRjJ2NUi5OFg3RC:jPh?=
SKOV3	M3\vW2N6fG:2b4jpZ4l1gSCjc4PhfS=>				NVHvW3RxS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hW0uRVkOgZ4VtdHNiYomgV3JDKGG\|c3H5MEBIUTVyIE2gNE4xODN\|IN88UU4>	M1zFVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NUi5OFg3Lz5{NEW4PVQ5PjxxYU6=
KM12	M3vmZ2N6fG:2b4jpZ4l1gSCjc4PhfS=>				MnX3R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gT20yOiClZXzsd{BjgSCVUlKgZZN{[XluIFfJOVAhRSByLkCwN\|Qh\|ryPLh?=	MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDV6OUS4Okc,OjR3OEm0PFY9N2F-
SF539	NFXPNYVEgXSxdH;4bYNqfHliYYPzZZk>				MUjDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDTSlU{QSClZXzsd{BjgSCVUlKgZZN{[XluIFfJOVAhRSByLkCwN\|Yh\|ryPLh?=	MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDV6OUS4Okc,OjR3OEm0PFY9N2F-
293T	MVvGeY5kfGmxbjDhd5NigQ>?		MUKzNEBucW6\|		M1X6U2lvcGmkaYTpc44hd2ZiaIXtZY4hUESDQ{Gg[ZhxemW\|c3XkJIlvKGi3bXHuJFI6O1RiY3XscJMhfXOrbnegRYMuU0eOR1uoRYMqNU2FQTDhd{B{fWK\|dILheIUh[W[2ZYKgN\|AhdWmwczDifUBndHWxcnXzZ4Vv[2ViYYPzZZktKEmFNUCgQUAxNjByM{[g{txONg>?	MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDV6OUS4Okc,OjR3OEm0PFY9N2F-
DMS114	MWLDfZRwfG:6aXPpeJkh[XO\|YYm=				NVG2b2toS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hTE2VMUG0JINmdGy\|IHL5JHNTSiCjc4PhfUwhT0l3MDC9JFAvODB\|NjFOwG0v	MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDV6OUS4Okc,OjR3OEm0PFY9N2F-
U251	M4\w[GN6fG:2b4jpZ4l1gSCjc4PhfS=>				NYjsOnNOS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hXTJ3MTDj[YxteyCkeTDTVmIh[XO\|YYmsJGdKPTBiPTCwMlAxOzlizszNMi=>	NYf0bmloRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS1PFk1QDZpPkK0OVg6PDh4PD;hQi=>
SF295	MW\DfZRwfG:6aXPpeJkh[XO\|YYm=				NELVPVVEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBUTjJ7NTDj[YxteyCkeTDTVmIh[XO\|YYmsJGdKPTBiPTCwMlAxPCEQvF2u	NIrqdY89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEW4PVQ5Pid-MkS1PFk1QDZ:L3G+
MCF7	M33zSmN6fG:2b4jpZ4l1gSCjc4PhfS=>				MkmyR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUWNHPyClZXzsd{BjgSCVUlKgZZN{[XluIFfJOVAhRSByLkCwOFIh\|ryPLh?=	M4\mPFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NUi5OFg3Lz5{NEW4PVQ5PjxxYU6=
OVCAR3	MYrDfZRwfG:6aXPpeJkh[XO\|YYm=				NHXQWJVEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBQXkODUkOgZ4VtdHNiYomgV3JDKGG\|c3H5MEBIUTVyIE2gNE4xODR4IN88UU4>	M1fUSlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NUi5OFg3Lz5{NEW4PVQ5PjxxYU6=
NCI-H23	MXHDfZRwfG:6aXPpeJkh[XO\|YYm=				NISzNG9EgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBPS0lvSEKzJINmdGy\|IHL5JHNTSiCjc4PhfUwhT0l3MDC9JFAvODB2NjFOwG0v	MlXiQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR3OEm0PFYoRjJ2NUi5OFg3RC:jPh?=
SF268	M3z3SWN6fG:2b4jpZ4l1gSCjc4PhfS=>				NWHkbnFnS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hW0Z{NkigZ4VtdHNiYomgV3JDKGG\|c3H5MEBIUTVyIE2gNE4xODR7IN88UU4>	MlHTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR3OEm0PFYoRjJ2NUi5OFg3RC:jPh?=
MKN7	M1vWVGN6fG:2b4jpZ4l1gSCjc4PhfS=>				NUiyb4Y2S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVUuQNzDj[YxteyCkeTDTVmIh[XO\|YYmsJGdKPTBiPTCwMlAxPDlizszNMi=>	NYLMO\|ZCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS1PFk1QDZpPkK0OVg6PDh4PD;hQi=>
OVCAR8	M4[3TGN6fG:2b4jpZ4l1gSCjc4PhfS=>				NHzsWXZEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBQXkODUkigZ4VtdHNiYomgV3JDKGG\|c3H5MEBIUTVyIE2gNE4xODV3IN88UU4>	NWL6UGpiRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS1PFk1QDZpPkK0OVg6PDh4PD;hQi=>
MDA-MB-231	NEDoTo9EgXSxdH;4bYNqfHliYYPzZZk>				MUjDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDNSGEuVUJvMkOxJINmdGy\|IHL5JHNTSiCjc4PhfUwhT0l3MDC9JFAvODB3NTFOwG0v	M{HUb\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NUi5OFg3Lz5{NEW4PVQ5PjxxYU6=
DMS273	Ml\PR5l1d3SxeHnjbZR6KGG\|c3H5				MonER5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gSG1UOjd\|IHPlcIx{KGK7IGPSRkBie3OjeTygS2k2OCB;IECuNFA2QCEQvF2u	M4DLe\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NUi5OFg3Lz5{NEW4PVQ5PjxxYU6=
DU145	M{SxXWN6fG:2b4jpZ4l1gSCjc4PhfS=>				M3zkZmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGRWOTR3IHPlcIx{KGK7IGPSRkBie3OjeTygS2k2OCB;IECuNFA3KM7:TT6=	M3LDNlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NUi5OFg3Lz5{NEW4PVQ5PjxxYU6=
RXF631L	M3jnU2N6fG:2b4jpZ4l1gSCjc4PhfS=>				NIXyWVNEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBTYEZ4M{HMJINmdGy\|IHL5JHNTSiCjc4PhfUwhT0l3MDC9JFAvODB4NjFOwG0v	MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDV6OUS4Okc,OjR3OEm0PFY9N2F-
HBC4	M1rMXWN6fG:2b4jpZ4l1gSCjc4PhfS=>				MVfDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDIRmM1KGOnbHzzJIJ6KFOUQjDhd5NigSxiR1m1NEA:KDBwMEC2PUDPxE1w	MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDV6OUS4Okc,OjR3OEm0PFY9N2F-
SNB75	NUnTPXpGS3m2b4TvfIlkcXS7IHHzd4F6				M{PoWGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJHNPSjd3IHPlcIx{KGK7IGPSRkBie3OjeTygS2k2OCB;IECuNFA4OiEQvF2u	MkDhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR3OEm0PFYoRjJ2NUi5OFg3RC:jPh?=
BSY1	M4\RXWN6fG:2b4jpZ4l1gSCjc4PhfS=>				NH7nN2dEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBDW1lzIHPlcIx{KGK7IGPSRkBie3OjeTygS2k2OCB;IECuNFA5PSEQvF2u	NGLSV\|A9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEW4PVQ5Pid-MkS1PFk1QDZ:L3G+
NCI-H226	M3zQcWN6fG:2b4jpZ4l1gSCjc4PhfS=>				NIrDPWlEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBPS0lvSEKyOkBk\WyuczDifUBUWkJiYYPzZZktKEeLNUCgQUAxNjByOEmg{txONg>?	MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDV6OUS4Okc,OjR3OEm0PFY9N2F-
SNB78	MXnDfZRwfG:6aXPpeJkh[XO\|YYm=				M{DVcmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJHNPSjd6IHPlcIx{KGK7IGPSRkBie3OjeTygS2k2OCB;IECuNFA6PiEQvF2u	MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDV6OUS4Okc,OjR3OEm0PFY9N2F-
HBC5	NHrFTIZEgXSxdH;4bYNqfHliYYPzZZk>				NIHFVoFEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBJSkN3IHPlcIx{KGK7IGPSRkBie3OjeTygS2k2OCB;IECuNFE{KM7:TT6=	MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDV6OUS4Okc,OjR3OEm0PFY9N2F-
MKN45	MlnUR5l1d3SxeHnjbZR6KGG\|c3H5				NFnKeIZEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBOU052NTDj[YxteyCkeTDTVmIh[XO\|YYmsJGdKPTBiPTCwMlAyPCEQvF2u	M2TB[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NUi5OFg3Lz5{NEW4PVQ5PjxxYU6=
MKN28	MnXsR5l1d3SxeHnjbZR6KGG\|c3H5				Mo\BR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUWtPOjhiY3XscJMh[nliU2LCJIF{e2G7LDDHTVUxKD1iMD6wNVch\|ryPLh?=	NULJe29URGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS1PFk1QDZpPkK0OVg6PDh4PD;hQi=>
PC3	M{DMeGN6fG:2b4jpZ4l1gSCjc4PhfS=>				M3;QSWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJHBEOyClZXzsd{BjgSCVUlKgZZN{[XluIFfJOVAhRSByLkCxPEDPxE1w	Mn3YQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR3OEm0PFYoRjJ2NUi5OFg3RC:jPh?=
ACHN	M2TuXGN6fG:2b4jpZ4l1gSCjc4PhfS=>				NHTlXpZEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBCS0iQIHPlcIx{KGK7IGPSRkBie3OjeTygS2k2OCB;IECuNFIh\|ryPLh?=	MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDV6OUS4Okc,OjR3OEm0PFY9N2F-
OVCAR4	M{LWdWN6fG:2b4jpZ4l1gSCjc4PhfS=>				MWPDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDPWmNCWjRiY3XscJMh[nliU2LCJIF{e2G7LDDHTVUxKD1iMD6wNkDPxE1w	MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDV6OUS4Okc,OjR3OEm0PFY9N2F-
St-4	NInUcnVEgXSxdH;4bYNqfHliYYPzZZk>				NGrN[olEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBUfC12IHPlcIx{KGK7IGPSRkBie3OjeTygS2k2OCB;IECuNFIzKM7:TT6=	M4LoZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NUi5OFg3Lz5{NEW4PVQ5PjxxYU6=
293T	MX\GeY5kfGmxbjDhd5NigQ>?		NXXncXlXOzBibXnudy=>		MlTWTY5pcWKrdHnvckBw\iCvb4Xz[UBJTEGFNjDlfJBz\XO\|ZXSgbY4hcHWvYX6gNlk{XCClZXzsd{B2e2mwZzDBZ{1MT0yJSzjBZ{kuVUODIHHzJJN2[nO2cnH0[UBi\nSncjCzNEBucW6\|IHL5JIZtfW:{ZYPj[Y5k\SCjc4PhfUwhUUN3MDC9JFAvOzlizszNMi=>	NH;JOGo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEW4PVQ5Pid-MkS1PFk1QDZ:L3G+
HCT15	MmKyR5l1d3SxeHnjbZR6KGG\|c3H5				Ml\SR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTGNVOTViY3XscJMh[nliU2LCJIF{e2G7LDDHTVUxKD1iMD60OUDPxE1w	MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDV6OUS4Okc,OjR3OEm0PFY9N2F-
mink Mv1Lu	MoDKSpVv[3Srb36gZZN{[Xl?		NFPoWYMzPCCqcoO=		MX\JcoNz\WG\|ZTDpckBpfW2jbjD3bYxlKHS7cHWgdFIyKHC{b4TlbY4h\XiycnXzd4lwdiCrbjDtbY5sKE24MVz1JINmdGy\|IHHmeIVzKDJ2IHjyd{BjgSCyMkGgdJJwdW:2ZYKgZZN{[XliaX6gdJJme2WwY3Wgc4YhOC5zIH3NJIRqfGirb4TodoVqfG:uLDDFR\|ExODBiPTCwMlAyPTdizszNMi=>	NGjvTVA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEm5O\|U4QCd-MkS5PVc2Pzh:L3G+
HCT116	NEi4bldCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		NGCzOGU1QCCqcoO=		NEW4flVCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjDWFEyPiClZXzsd{Bi\nSncjC0PEBpenNiaX6gdJJme2WwY3Wgc4YhTFSWIHL5JG1VXCCjc4PhfUwhUUN3MDC9JFAvODB\|IN88UU4>	MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTF2N{[xNkc,OjVzNEe2NVI9N2F-
MOLT4	NWn2cmZ7SW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		Mne5O\|IhcHK\|		NULkO49nSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDNU2xVPCClZXzsd{Bi\nSncjC3NkBpenNiYomgR2NMQCCjc4PhfUwhT0l3MDC9JFAvODB{ME[g{txONg>?	MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjN\|MUOzOEc,OjZ\|M{GzN\|Q9N2F-
DU145	NIH6eGtCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		MVK3NkBpenN?		M33UU2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iRGWxOFUh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IFPDT\|gh[XO\|YYmsJGdKPTBiPTCwMlAxOjV3IN88UU4>	MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjN\|MUOzOEc,OjZ\|M{GzN\|Q9N2F-
U937	NFTRXVBCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		NWfqRWhwPzJiaILz		MV\BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKFV7M{egZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KEOFS{igZZN{[XluIFfJOVAhRSByLkCwN\|QyKM7:TT6=	M{DVc\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4M{OxN\|M1Lz5{NkOzNVM{PDxxYU6=
HLF	MUjBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		MUK3NkBpenN?		MkC3RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCKTF[gZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KEOFS{igZZN{[XluIFfJOVAhRSByLkCwOFg6KM7:TT6=	Mo[zQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ\|M{GzN\|QoRjJ4M{OxN\|M1RC:jPh?=
WI38	MkLPRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		MV23NkBpenN?		NXvYT\|M5SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDXTVM5KGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDDR2s5KGG\|c3H5MEBIUTVyIE2gNE4xODV\|OTFOwG0v	M1PwblxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4M{OxN\|M1Lz5{NkOzNVM{PDxxYU6=
U937	MXfGeY5kfGmxbjDhd5NigQ>?		MXyyOEBpenN?		MXLJcohq[mm2aX;uJI9nKEiGQVO2JIlvKGi3bXHuJHU6OzdiY3XscJMh[XO\|ZYPz[YQh[XNicnXkeYN1cW:wIH;mJIFteGijLYT1ZoltcW5iYXPleJlt[XSrb36gZZQhPSCwTTD0c{A2KHWPIHHmeIVzKDJ2IHjyd{BjgSCZZYP0[ZJvKGKub4SgZY5idHm\|aYO=	M3PwN\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4M{OxN\|M1Lz5{NkOzNVM{PDxxYU6=
HCT116	NUjCO4sxSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		NVe1[olUPzJiaILz		Ml7IRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCKQ2SxNVYh[2WubIOgZZN{\XO\|ZXSgZZMh[2WubDD2bYFjcWyrdImgbY5kfWKjdHXkJIZweiB5MjDodpMh[nliY3;1cJRmeiClb4XueIVzKG2ndHjv[EwhUUN3MDC9JFAvODJ6IN88UU4>	MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjR6MU[1PUc,OjZ2OEG2OVk9N2F-
IGROV1/Pt1	NGPE[FFCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		M3v5SVczKGi{cx?=		NYPLSGx1SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDJS3JQXjFxUISxJINmdGy\|IHHzd4V{e2WmIHHzJINmdGxidnnhZoltcXS7IHnuZ5Vj[XSnZDDmc5IhPzJiaILzJIJ6KGOxdXz0[ZIh[2:3boTldkBu\XSqb3SsJGlEPTBiPTCwMlA5KM7:TT6=	MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjR6MU[1PUc,OjZ2OEG2OVk9N2F-
IGROV1	NEfvOJlCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		Mlm4O\|IhcHK\|		MUPBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEmJUl;WNUBk\WyuczDhd5Nme3OnZDDhd{Bk\WyuII\pZYJqdGm2eTDpcoN2[mG2ZXSg[o9zKDd{IHjyd{BjgSClb4XseIVzKGOxdX70[ZIhdWW2aH;kMEBKSzVyIE2gNE4zOiEQvF2u	NXTFd4k2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[0PFE3PTlpPkK2OFgyPjV7PD;hQi=>

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	p21 / Cyclin D1; PubMed: 19682393 J Mol Signal NIH 3T3 cells stably expressing the indicated proteins were treated with DMSO (Vehicle) or the indicated concentration of romidepsin for 24 h. Cell lysates were analyzed by western blotting with antibodies to cyclin D1, p21 and β-actin (loading control). Data shown are representative of at least two independent experiments. AcH3(K9) / Ac-α-Tubulin(K40) / Ac-NFκB2(K310) p65 / 3MeH3(K27); PubMed: 26473529 Blood Cancer J Effects of romidepsin (Rom) on the levels of acetylated proteins and related enzymes. Cells were exposed to romidepsin for 48 h and total cell extracts were analyzed by western blot. HDAC3 / HDAC4 / HDAC6 / HDAC2; PubMed: 26473529 Blood Cancer J Effects of romidepsin (Rom) on the levels of acetylated proteins and related enzymes. Cells were exposed to romidepsin for 48 h and total cell extracts were analyzed by western blot. γH2AX / PARP1 / Cleaved caspase3 / BAK / p21(waf1/cip1) / XIAP; PubMed: 26473529 Blood Cancer J Western blot analysis of proteins involved in DNA-damage response and apoptosis. Established cell lines were exposed to different concentrations of romidepsin (Rom) for 48 h and total cell extracts were analyzed. Cyclin E1 / BRCA1 / E2F1 / Cleaved PARP / H3Ac; PubMed: 27444036 Gynecol Oncol Western blot analysis of the effects of panobinostat (25 nM), vorinostat (5 µM) and romidepsin (10 nM) on expression of cyclin E1, E2F1, BRCA1, cleaved PARP and acetylated histone H3 in OVCAR-3 cells. Actin and histone H3 were loading controls. pAKT(S473) / pAKT(T308) / AKT; PubMed: 25492515 Cancer Sci Western blot analysis of phosphorylated AKT in PC3 cells. Cells were treated for 3 h with various concentrations of FK228.	19682393 26473529 27444036 25492515
Growth inhibition assay	Cell viability; PubMed: 27444036 Gynecol Oncol Concentration-dependent effects of panobinostat and vorinostat in SRB viability assays in OVCAR-3 cells (72 h). Values are mean+SE of 3 independent experiments.	27444036
Immunofluorescence	SS18/TLE1; PubMed: 27120803 Oncotarget A significant decrease in detectable PLA signal following HDAC inhibition in SYO-1 cells. Cleaved caspase-3; PubMed: 22531354 J Ovarian Res TDP-B activates cleaved caspase-3 by immunofluorescence. Representative immunofluorescence staining for cleaved caspase 3 (green) in SKOV-3 ovarian cancer cells treated with 10 nM FK228, TDP-A or TDP-B after 24 h of exposure. The nuclei are stained with DAPI (blue).	27120803 22531354

In vivo

Romidepsin treatment potently inhibits the neovascularization of chick embryo and that of adult mice in the Matrigel plug assay. ^[4]Administration of Romidepsin at 0.1-1 mg/kg twice a week significantly prolongs the survival of mice bearing U-937 lymphoma, with median survival times of 30.5 (0.56 mg/kg) and 33 days (0.32 mg/kg), respectively (vs. 20 days in control mice). ^[5]

Protocol

Kinase Assay: ^[1]	- Collapse HDAC-inhibitory activity: For the enzyme assay, 10 μL of [³H]acetyl-labeled histones (25,000 cpm/10 μg) are added to 90 μL of the HDAC enzyme fraction extracted from 293T cells overexpressing HDAC1 or HDAC2 in the presence of increasing concentrations of Romidepsin, and the mixture is incubated at 37 °C for 15 minutes. The enzyme reaction is linear for at least 1 hour. The reaction is stopped by the addition of 10 μL of concentrated HCl. The released [³H]acetic acid is extracted with 1 mL of ethylacetate, and 0.9 mL of the solvent layer is taken into 5 mL of aqueous counting scintillant II solution for determination of radioactivity. The IC50 values are determined from at least three independent dose-response curves.
Cell Research: ^[3]	- Collapse Cell lines: HL60, Jurkat, A549, and MCF-7 Concentrations: Dissolved in DMSO, final concentrations ~10 μM Incubation Time: 72 hours Method: Cells are exposed to various concentrations of Romidepsin for 72 hours in 96-well plates. 20 μL of 5 mg/mL MTT solution in PBS is added to each well for 4 hours. After removal of the medium, 170 μL of DMSO is added to each well to dissolve the formazan crystals. The absorbance at 540 nm is determined. In addition, cells are incubated with trypan blue, and the numbers of blue (dead) cells and transparent (live) cells are counted in a hemocytometer. For cell cycle analysis, cells are incubated for 30 minutes in propidium iodide staining solution containing 0.05 mg/mL propidium iodide, 1 mM EDTA, 0.1% Triton X-100, and 1 mg/mL RNase A in PBS. The suspension is then passed through a nylon mesh filter and analyzed on a Becton Dickinson FACScan. (Only for Reference)
Animal Research: ^[5]	- Collapse Animal Models: Male scid mice inoculated i.p. with U-937 cells Dosages: ~1 mg/kg once or twice a week Administration: Treated i.p. (Only for Reference)

References

- Collapse

Solubility (25°C)

In vitro	DMSO	10 mg/mL (18.49 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 2% DMSO+30% PEG 300+5%Tween 80+ddH2O For best results, use promptly after mixing.	5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight	540.7
Formula	C₂₄H₃₆N₄O₆S₂
CAS No.	128517-07-7
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	FR 901228, NSC 630176
Smiles	CC=C1C(=O)NC(C(=O)OC2CC(=O)NC(C(=O)NC(CSSCCC=C2)C(=O)N1)C(C)C)C(C)C

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take μL DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2021-01-06)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT03770000	Active not recruiting	Drug: Tenalisib\|Drug: Romidepsin	T Cell Lymphoma	Rhizen Pharmaceuticals SA	March 12 2019	Phase 1\|Phase 2
NCT02616965	Recruiting	Drug: Romidepsin\|Drug: Brentuximab vedotin	Cutaneous T-cell Lymphoma (CTCL)	Fox Chase Cancer Center\|Seagen Inc.\|Celgene Corporation	February 22 2017	Phase 1
NCT02616874	Completed	Drug: MVA.HIVconsv vaccine\|Drug: Romidepsin	HIV	IrsiCaixa\|Germans Trias i Pujol Hospital\|Fundación FLS de Lucha Contra el Sida las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia\|Hospital Clinic of Barcelona\|Hospital de Sant Pau\|HIVACAT\|University of Oxford\|BCN Checkpoint	February 2016	Phase 1
NCT03141203	Active not recruiting	Drug: Romidepsin\|Drug: Carfilzomib	Peripheral T Cell Lymphoma	University of Birmingham\|Bloodwise\|Celgene\|Amgen	July 13 2015	Phase 1\|Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

Pan HDAC Inhibitor

Panobinostat (LBH589) : Pan-HDAC inhibitor, IC50=5 nM.
Most Potent HDAC Inhibitor

Quisinostat (JNJ-26481585) : HDAC1, IC50=0.11 nM; HDAC2, IC50=0.33 nM.
FDA-approved HDAC Inhibitor

Vorinostat (SAHA, MK0683) : Approved by FDA against cutaneous T cell lymphoma.
Newest HDAC Inhibitor

RG2833 (RGFP109) ^New : Brain-penetrant HDAC inhibitor with IC50 of 60 nM and 50 nM for HDAC1 and HDAC3, respectively.

Related HDAC Products

LMK-235 ^New

LMK-235 is a selective inhibitor of HDAC4 and HDAC5 with IC50 of 11.9 nM and 4.2 nM, respectively.
CAY10603 ^New

CAY10603 (BML-281) is a potent and selective HDAC6 inhibitor with IC50 of 2 pM, >200-fold selectivity over other HDACs.
Domatinostat (4SC-202) ^New

Domatinostat (4SC-202) is a selective class I HDAC inhibitor with IC50 of 1.20 μM, 1.12 μM, and 0.57 μM for HDAC1, HDAC2, and HDAC3, respectively. Also displays inhibitory activity against Lysine specific demethylase 1 (LSD1). Phase 1.
Panobinostat (LBH589)

Panobinostat (LBH589, NVP-LBH589) is a novel broad-spectrum HDAC inhibitor with IC50 of 5 nM in a cell-free assay. Panobinostat (LBH589) induces autophagy and apoptosis. Panobinostat effectively disrupts HIV latency in vivo. Phase 3.
Vorinostat (SAHA)

Vorinostat (suberoylanilide hydroxamic acid, SAHA, MK0683) is an HDAC inhibitor with IC50 of ~10 nM in a cell-free assay. Vorinostat abrogates productive HPV-18 DNA amplification.
Entinostat (MS-275)

Entinostat (MS-275, SNDX-275) strongly inhibits HDAC1 and HDAC3 with IC50 of 0.51 μM and 1.7 μM in cell-free assays, compared with HDACs 4, 6, 8, and 10. Entinostat induces autophagy and apoptosis. Phase 3.
Trichostatin A (TSA)

Trichostatin A (TSA) is an HDAC inhibitor with IC50 of ~1.8 nM in cell-free assays.
RGFP966

RGFP966 is an HDAC3 inhibitor with IC50 of 0.08 μM in cell-free assay, exhibits > 200-fold selectivity over other HDAC.
Tubastatin A

Tubastatin A is a potent and selective HDAC6 inhibitor with IC50 of 15 nM in a cell-free assay. It is selective against all the other isozymes (1000-fold) except HDAC8 (57-fold). Tubastatin A promotes autophagy and increases apoptosis.
Mocetinostat (MGCD0103)

Mocetinostat (MGCD0103, MG0103) is a potent HDAC inhibitor with most potency for HDAC1 with IC50 of 0.15 μM in a cell-free assay, 2- to 10- fold selectivity against HDAC2, 3, and 11, and no activity to HDAC4, 5, 6, 7, and 8. Mocetinostat (MGCD0103) induces apoptosis and autophagy. Phase 2.

Choose Your Country or Region

By Signaling Pathways

By product type

Romidepsin (FK228, Depsipeptide)